101 results on '"Stephen H. Petersdorf"'
Search Results
2. Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
- Author
-
Roland B. Walter, Megan Othus, Bob Löwenberg, Gert J. Ossenkoppele, Stephen H. Petersdorf, Thomas Pabst, Marie-Christiane Vekemans, Frederick R. Appelbaum, Harry P. Erba, and Elihu H. Estey
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2015
- Full Text
- View/download PDF
3. Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
- Author
-
Ram N. Ganapathi, Cheryl L. Willman, Frederick R. Appelbaum, Jerald P. Radich, John E. Godwin, Eric R. Koegle, Shannon McDonough, Megan Othus, Stephen H. Petersdorf, Anjali S. Advani, Mahrukh K. Ganapathi, Andrew P. Michelson, and Alan F. List
- Subjects
Male ,lcsh:Medicine ,Cohort Studies ,0302 clinical medicine ,Immunophenotyping ,Topoisomerase II Inhibitors ,Poly-ADP-Ribose Binding Proteins ,lcsh:Science ,Cancer ,Aged, 80 and over ,0303 health sciences ,Multidisciplinary ,biology ,Cytarabine ,Middle Aged ,3. Good health ,Leukemia, Myeloid, Acute ,Leukemia ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,medicine.drug ,Adult ,Cell biology ,Anthracycline ,Daunorubicin ,CD14 ,Antineoplastic Agents ,Article ,Young Adult ,03 medical and health sciences ,Myelogenous ,Antigens, CD ,medicine ,Humans ,RNA, Messenger ,Aged ,030304 developmental biology ,business.industry ,Topoisomerase ,lcsh:R ,Adult Acute Myeloid Leukemia ,medicine.disease ,DNA Topoisomerases, Type II ,biology.protein ,Cancer research ,lcsh:Q ,business - Abstract
Anthracyclines used in the treatment of acute myelogenous leukemia (AML) inhibit the activity of the mammalian topoisomerase II (topo II) isoforms, topo II α and topo IIβ. In 230 patients with non-M3 AML who received frontline ara-C/daunorubicin we determined expression of topo IIα and topo IIβ by RT-PCR and its relationship to immunophenotype (IP) and outcomes. Treatment outcomes were analyzed by logistic or Cox regression. In 211 patients, available for analysis, topo IIα expression was significantly lower than topo IIβ (P
- Published
- 2020
4. Effect of Measurable ('Minimal') Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
- Author
-
Derek L. Stirewalt, Elihu H. Estey, Brent L. Wood, Megan Othus, Harry P. Erba, Roland B. Walter, Frederick R. Appelbaum, and Stephen H. Petersdorf
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Myeloid ,Neoplasm, Residual ,Article ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Survival analysis ,Hematology ,business.industry ,Adult Acute Myeloid Leukemia ,medicine.disease ,Minimal residual disease ,Survival Analysis ,3. Good health ,Lymphoma ,body regions ,Leukemia ,Haematopoiesis ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Immunology ,business ,030215 immunology - Abstract
Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia
- Published
- 2016
5. Prognostic Significance of NPM1 Mutations in the Absence of FLT3–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report
- Author
-
Fabiana Ostronoff, Min Fang, Jerald P. Radich, Soheil Meshinchi, Stephen H. Petersdorf, Michelle Lazenby, Alan F. List, Alan Kenneth Burnett, Elihu H. Estey, Cheryl L. Willman, Anna Evans, Era L. Pogosova-Agadjanyan, John E. Godwin, Frederick R. Appelbaum, Kenneth J. Kopecky, Vivian G. Oehler, Megan Othus, Derek L. Stirewalt, and Amanda F. Gilkes
- Subjects
Male ,FLT3 Internal Tandem Duplication ,Cancer Research ,NPM1 ,Multivariate analysis ,Genotype ,MEDLINE ,medicine ,Humans ,Survival analysis ,Aged ,Clinical Trials as Topic ,business.industry ,Age Factors ,Nuclear Proteins ,Myeloid leukemia ,ORIGINAL REPORTS ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,United Kingdom ,United States ,Leukemia ,Treatment Outcome ,fms-Like Tyrosine Kinase 3 ,Oncology ,Leukemia, Myeloid ,Tandem Repeat Sequences ,Acute Disease ,Multivariate Analysis ,Mutation ,Cancer research ,Female ,Erratum ,business ,Nucleophosmin - Abstract
Purpose Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3–internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD–negative genotype) are classified as better risk; however, it remains uncertain whether this favorable classification can be applied to older patients with AML with this genotype. Therefore, we examined the impact of age on the prognostic significance of NPM1-positive/FLT3-ITD–negative status in older patients with AML. Patients and Methods Patients with AML age ≥ 55 years treated with intensive chemotherapy as part of Southwest Oncology Gorup (SWOG) and UK National Cancer Research Institute/Medical Research Council (NCRI/MRC) trials were evaluated. A comprehensive analysis first examined 156 patients treated in SWOG trials. Validation analyses then examined 1,258 patients treated in MRC/NCRI trials. Univariable and multivariable analyses were used to determine the impact of age on the prognostic significance of NPM1 mutations, FLT3-ITDs, and the NPM1-positive/FLT3-ITD–negative genotype. Results Patients with AML age 55 to 65 years with NPM1-positive/FLT3-ITD–negative genotype treated in SWOG trials had a significantly improved 2-year overall survival (OS) as compared with those without this genotype (70% v 32%; P < .001). Moreover, patients age 55 to 65 years with NPM1-positive/FLT3-ITD–negative genotype had a significantly improved 2-year OS as compared with those age > 65 years with this genotype (70% v 27%; P < .001); any potential survival benefit of this genotype in patients age > 65 years was marginal (27% v 16%; P = .33). In multivariable analysis, NPM1-positive/FLT3-ITD–negative genotype remained independently associated with an improved OS in patients age 55 to 65 years (P = .002) but not in those age > 65 years (P = .82). These results were confirmed in validation analyses examining the NCRI/MRC patients. Conclusion NPM1-positive/FLT3-ITD–negative genotype remains a relatively favorable prognostic factor for patients with AML age 55 to 65 years but not in those age > 65 years.
- Published
- 2015
6. Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy
- Author
-
Marilyn L. Slovak, Martin S. Tallman, Joseph M. Brandwein, Patrick J. Stiff, Roland B. Walter, Frederick R. Appelbaum, Kenneth J. Kopecky, Thomas J. Nevill, Megan Othus, Richard A. Larson, Leif Stenke, Harry P. Erba, and Stephen H. Petersdorf
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Human leukocyte antigen ,Disease-Free Survival ,Article ,Internal medicine ,medicine ,Humans ,Induction failure ,Survival rate ,Preparative Regimen ,Transplantation ,Acute myeloid leukemia ,Hematopoietic cell transplantation ,business.industry ,Histocompatibility Testing ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Induction chemotherapy ,Induction Chemotherapy ,Hematology ,Middle Aged ,Allografts ,3. Good health ,Survival Rate ,Leukemia, Myeloid, Acute ,Cohort ,Immunology ,Female ,business - Abstract
The aim of this study was to describe the fate of patients with newly diagnosed acute myeloid leukemia (AML) who did not achieve an initial remission while being treated on a contemporary cooperative group trial. We analyzed the outcome of patients entered into S0106, a recently reported cooperative group trial for patients with newly diagnosed AML. A total of 589 eligible patients was treated, of whom 150 (25%) did not achieve a remission while on study and were available for further analysis. The 4-year survival rate for the entire cohort of 150 patients was 23%. Among the 64 patients who received an allogeneic hematopoietic cell transplant, the 4-year survival rate was 48% compared with 4% for the 86 patients who did not undergo transplantation. Among those transplanted, we could not detect a difference in outcome according to remission status, donor source, type of preparative regimen, or cytogenetic risk category. More than 20% of patients with newly diagnosed AML who fail induction therapy can still be cured, particularly if they are able to receive an allogeneic hematopoietic cell transplant. These results suggest that early HLA typing and donor identification are important components of the initial therapy of AML.
- Published
- 2015
7. Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI
- Author
-
Elihu H. Estey, Megan Othus, Nigel H. Russell, Bob Löwenberg, Alan Kenneth Burnett, Frederick R. Appelbaum, Sucha Nand, Wim H. van der Putten, Stephen H. Petersdorf, Harry P. Erba, Robert Kerrin Hills, and Hematology
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Adolescent ,Disease-Free Survival ,Food and drug administration ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Humans ,Online Only Articles ,Aged ,Aged, 80 and over ,business.industry ,Surrogate endpoint ,Event free survival ,Myeloid leukemia ,Hematology ,Middle Aged ,Survival Rate ,Leukemia, Myeloid, Acute ,Sample size determination ,030220 oncology & carcinogenesis ,Female ,business ,030215 immunology - Abstract
Much recent attention has been given to evaluating surrogate endpoints for overall survival (OS) in various cancers. Valid surrogate endpoints for OS can reduce sample size, reduce follow-up duration, and decrease costs for trials. The US Food and Drug Administration (FDA) has approved new drugs in
- Published
- 2016
8. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- Author
-
Lucy Chilton, Jacques Delaunay, Anthony V. Moorman, Stephen H. Petersdorf, Norbert Ifrah, Christian Recher, Frederick R. Appelbaum, Megan Othus, Alan Kenneth Burnett, Jean-Yves Cahn, Sylvie Castaigne, Robert Kerrin Hills, Sylvie Chevret, Elihu H. Estey, and Hervé Dombret
- Subjects
Adult ,Male ,medicine.medical_specialty ,Gemtuzumab ozogamicin ,medicine.medical_treatment ,Enasidenib ,Antibodies, Monoclonal, Humanized ,Risk Assessment ,Disease-Free Survival ,Drug Administration Schedule ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Confidence Intervals ,Odds Ratio ,Clinical endpoint ,medicine ,Humans ,Infusions, Intravenous ,Intensive care medicine ,Survival rate ,Randomized Controlled Trials as Topic ,Chemotherapy ,Dose-Response Relationship, Drug ,business.industry ,Daunorubicin ,Remission Induction ,Cytarabine ,Induction chemotherapy ,Odds ratio ,Middle Aged ,Prognosis ,Gemtuzumab ,Survival Rate ,Leukemia, Myeloid, Acute ,Aminoglycosides ,Treatment Outcome ,Oncology ,Meta-analysis ,Female ,business ,medicine.drug - Abstract
Summary Background Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acute myeloid leukaemia. However, randomised trials in which it was combined with standard induction chemotherapy in adults have produced conflicting results. We did a meta-analysis of individual patient data to assess the efficacy of adding gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia. Methods We searched PubMed for reports of randomised controlled trials published in any language up to May 1, 2013, that included an assessment of gemtuzumab ozogamicin given to adults (aged 15 years and older) in conjunction with the first course of intensive induction chemotherapy for acute myeloid leukaemia (excluding acute promyelocytic leukaemia) compared with chemotherapy alone. Published data were supplemented with additional data obtained by contacting individual trialists. The primary endpoint of interest was overall survival. We used standard meta-analytic techniques, with an assumption-free (or fixed-effect) method. We also did exploratory stratified analyses to investigate whether any baseline features predicted a greater or lesser benefit from gemtuzumab ozogamicin. Findings We obtained data from five randomised controlled trials (3325 patients); all trials were centrally randomised and open label, with overall survival as the primary endpoint. The addition of gemtuzumab ozogamicin did not increase the proportion of patients achieving complete remission with or without complete peripheral count recovery (odds ratio [OR] 0·91, 95% CI 0·77–1·07; p=0·3). However, the addition of gemtuzumab ozogamicin significantly reduced the risk of relapse (OR 0·81, 0·73–0·90; p=0·0001), and improved overall survival at 5 years (OR 0·90, 0·82–0·98; p=0·01). At 6 years, the absolute survival benefit was especially apparent in patients with favourable cytogenetic characteristics (20·7%; OR 0·47, 0·31–0·73; p=0·0006), but was also seen in those with intermediate characteristics (5·7%; OR 0·84, 0·75–0·95; p=0·005). Patients with adverse cytogenetic characteristics did not benefit (2·2%; OR 0·99, 0·83–1·18; p=0·9). Doses of 3 mg/m 2 were associated with fewer early deaths than doses of 6 mg/m 2 , with equal efficacy. Interpretation Gemtuzumab ozogamicin can be safely added to conventional induction therapy and provides a significant survival benefit for patients without adverse cytogenetic characteristics. These data suggest that the use of gemtuzumab ozogamicin should be reassessed and its licence status might need to be reviewed. Funding None.
- Published
- 2014
9. Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
- Author
-
Elihu H. Estey, Bob Löwenberg, Frederick R. Appelbaum, Harry P. Erba, Roland B. Walter, Megan Othus, Thomas Pabst, Gert J. Ossenkoppele, Marie Christiane Vekemans, Stephen H. Petersdorf, Hematology, and CCA - Innovative therapy
- Subjects
Oncology ,Clinical Trials as Topic ,medicine.medical_specialty ,business.industry ,Remission Induction ,Complete remission ,Myeloid leukemia ,Adult Acute Myeloid Leukemia ,Hematology ,Therapeutic resistance ,Clinical trial ,Leukemia, Myeloid, Acute ,Treatment Outcome ,Refractory ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Relapsed refractory ,medicine ,Humans ,Online Only Articles ,business ,Intensive care medicine - Abstract
Despite incremental progress over the last several decades, adult acute myeloid leukemia (AML) remains difficult to treat, and many patients experience therapeutic resistance, i.e. never attain a complete remission (CR) despite living long enough to have done so (i.e. are “primary refractory”)
- Published
- 2015
10. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- Author
-
Martin S. Tallman, Marilyn L. Slovak, Joseph M. Brandwein, Frederick R. Appelbaum, Harry P. Erba, Richard A. Larson, Roland B. Walter, Cheryl L. Willman, Patrick J. Stiff, Stephen H. Petersdorf, Robert K. Stuart, Thomas J. Nevill, Kenneth J. Kopecky, and Leif Stenke
- Subjects
Male ,medicine.medical_specialty ,Randomization ,Clinical Trials and Observations ,Daunorubicin ,Gemtuzumab ozogamicin ,Immunology ,Phases of clinical research ,Pharmacology ,Enasidenib ,Antibodies, Monoclonal, Humanized ,Biochemistry ,Gastroenterology ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Survival rate ,business.industry ,Induction chemotherapy ,Cell Biology ,Hematology ,Gemtuzumab ,Consolidation Chemotherapy ,Leukemia, Myeloid, Acute ,Aminoglycosides ,Cytarabine ,Female ,business ,medicine.drug - Abstract
This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in patients with acute myeloid leukemia. Patients were randomly assigned to receive daunorubicin (45 mg/m2 per day on days 1, 2, and 3), cytarabine (100 mg/m2 per day by continuous infusion on days 1–7), and GO (6 mg/m2 on day 4; DA+GO) vs standard induction therapy with daunorubicin (60 mg/m2 per day on days 1, 2, and 3) and cytarabine alone (DA). Patients who achieved complete remission (CR) received 3 courses of high-dose cytarabine. Those remaining in CR after consolidation were randomly assigned to receive either no additional therapy or 3 doses of GO (5 mg/m2 every 28 days). From August 2004 until August 2009, 637 patients were registered for induction. The CR rate was 69% for DA+GO and 70% for DA (P = .59). Among those who achieved a CR, the 5-year relapse-free survival rate was 43% in the DA+GO group and 42% in the DA group (P = .40). The 5-year overall survival rate was 46% in the DA+GO group and 50% in the DA group (P = .85). One hundred seventy-four patients in CR after consolidation underwent the postconsolidation randomization. Disease-free survival was not improved with postconsolidation GO (HR, 1.48; P = .97). In this study, the addition of GO to induction or postconsolidation therapy failed to show improvement in CR rate, disease-free survival, or overall survival. This trial is registered with www.clinicaltrials.gov as #NCT00085709.
- Published
- 2013
11. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson
- Author
-
Frederick R. Appelbaum, Megan Othus, Stephen H. Petersdorf, Elihu H. Estey, Harry P. Erba, Farhad Ravandi, John E. Godwin, Stefan Faderl, Hagop M. Kantarjian, Jorge E. Cortes, and Sherry Pierce
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Myeloid ,Adolescent ,Article ,Young Adult ,Internal medicine ,White blood cell ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Young adult ,Aged ,Retrospective Studies ,Aged, 80 and over ,Performance status ,business.industry ,Induction chemotherapy ,Myeloid leukemia ,Retrospective cohort study ,Induction Chemotherapy ,Hematology ,Middle Aged ,medicine.disease ,Surgery ,Leukemia, Myeloid, Acute ,Leukemia ,Treatment Outcome ,medicine.anatomical_structure ,business - Abstract
Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this assumption. We examined TRM rates in 1409 patients treated on SWOG (Southwest Oncology Group) trials and 1942 patients treated at MD Anderson (MDA) from 1991 to 2009. Eighty-eight percent of SWOG patients received '3+7' or regimens of similar intensity while 92% of the MDA patients received ara-C at 1.5-2.0 g/m(2) daily × 3-5 days+other cytotoxic agents. We examined the relationship between time and TRM rates after accounting for other covariates. TRM rates between 1991 and 2009 decreased from 18-3% in SWOG and 16-4% at MDA. Multivariate analyses showed a significant decrease in TRM over time (P=0.001). The decrease in TRM was not limited to younger patients, those with a better performance status or a lower white blood cell count. Though our observations are limited to patients treated with intensive therapy at SWOG institutions and MDA, the decrease in TRM with time emphasizes the problem with historical controls and could be considered when selecting AML induction therapy.
- Published
- 2013
12. Senior Adult Oncology
- Author
-
Jimmie C. Holland, Ilene S. Browner, Apar Kishor Ganti, Tanya M. Wildes, June M. McKoy, Mohana Karlekar, Hope S. Rugo, Harvey J. Cohen, Nancy L. Keating, Mollie deShazo, Bruno C. Medeiros, William P. Tew, Alva B. Weir, Tracey O'Connor, Arti Hurria, Holly M. Holmes, Crystal S. Denlinger, Rebecca A. Silliman, Stephen H. Petersdorf, Ewa Mrozek, Martine Extermann, and Louise C. Walter
- Subjects
Adult ,Geriatrics ,medicine.medical_specialty ,business.industry ,MEDLINE ,Neoplasms therapy ,Medical Oncology ,Article ,Cancer treatment ,Oncology ,Neoplasms ,medicine ,Humans ,Intensive care medicine ,business ,Aged - Published
- 2012
13. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
- Author
-
Elihu H. Estey, Hagop M. Kantarjian, Stephan Faderl, Jianqin Shan, Barry E. Storer, Andrei R. Shustov, Stephen H. Petersdorf, Sherry Pierce, Derek L. Stirewalt, John M. Pagel, Paul C. Hendrie, Elizabeth Harrington, Frederick R. Appelbaum, and Pamela S. Becker
- Subjects
medicine.medical_specialty ,Chemotherapy ,Myeloid ,business.industry ,medicine.medical_treatment ,Salvage therapy ,Hematology ,Pharmacology ,medicine.disease ,Gastroenterology ,Granulocyte colony-stimulating factor ,Leukemia ,medicine.anatomical_structure ,Internal medicine ,Toxicity ,Cytarabine ,medicine ,Clofarabine ,business ,medicine.drug - Abstract
This phase I/II study was conducted to determine the maximum tolerated dose, toxicity, and efficacy of clofarabine in combination with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming (GCLAC), in the treatment of patients with relapsed or refractory acute myeloid leukaemia (AML). Dose escalation of clofarabine occurred without dose-limiting toxicity, so most patients were treated at the maximum dose, 25 mg/m(2) per day with cytarabine 2 g/m(2) per day, each for 5 d, and G-CSF 5 μg/kg, beginning the day before chemotherapy and continuing daily until neutrophil recovery. The complete remission (CR) rate among the 46 evaluable patients was 46% (95% confidence interval [CI] 31-61%) and the CR + CR but with a platelet count
- Published
- 2011
14. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
- Author
-
Anjali S. Advani, Stephen H. Petersdorf, Mikkael A. Sekeres, Cheryl L. Willman, Alan F. List, Jeffrey E. Lancet, Deborah Mulford, Holly Gundacker, Tom Norwood, Frederick R. Appelbaum, and Jane L. Liesveld
- Subjects
Male ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Antineoplastic Agents ,Biochemistry ,Maintenance therapy ,Internal medicine ,medicine ,Humans ,Lenalidomide ,Survival rate ,Aged ,Aged, 80 and over ,Chemotherapy ,business.industry ,Myeloid leukemia ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Chemotherapy regimen ,Thalidomide ,Survival Rate ,Leukemia, Myeloid, Acute ,Leukemia ,Treatment Outcome ,Chromosomes, Human, Pair 5 ,Female ,Chromosome Deletion ,business ,medicine.drug - Abstract
Older acute myeloid leukemia (AML) patients with a chromosome 5q deletion have poor outcomes with conventional chemotherapy. This phase 2 study explored the safety and efficacy of single-agent lenalidomide in previously untreated older AML patients with del(5q) who declined standard chemotherapy. Patients were treated with lenalidomide 50 mg daily for 28 days as induction therapy and 10 mg daily for 21 days of a 28-day cycle as maintenance until disease progression or unacceptable toxicity. Among 37 evaluable patients, the median age was 74 years (range, 60-94), 21 (57%) were female, 19 (51%) had prior myelodysplastic syndrome, and 30 (81%) had pretreatment cytogenetic studies evaluated centrally. Six had isolated del(5q), 1 had del(5q) and +8, 23 had complex cytogenetics, and 7 others had del(5q) identified locally. Fourteen patients (38%) completed induction therapy: 7 patients died during induction therapy, 8 had disease progression, 7 had nonfatal adverse events, and 1 entered hospice. Eight patients started maintenance therapy. Five patients (14%) achieved a partial or complete response, 2 with isolated del(5q) and 3 with complex cytogenetics. Relapse-free survival was 5 months (range, 0-19). Median overall survival was 2 months for the entire population. In conclusion, lenalidomide as a single agent has modest activity in older del(5q) AML patients. Southwest Oncology Group Study S0605 is registered at www.clinicaltrials.gov as NCT00352365.
- Published
- 2011
15. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- Author
-
Mark R. Litzow, Lothar Tremmel, Dan Douer, Anjali S. Advani, Maria R. Baer, Martin S. Tallman, Takashi Sato, Harry P. Erba, B. Douglas Smith, Wieslaw Wiktor-Jedrzejczak, Steven Coutre, Donald Small, Robert K. Stuart, Miguel A. Sanz, Larry D. Cripe, Sergio Amadori, Giovanna Meloni, Hagop M. Kantarjian, Ian D. Lewis, Michele Baccarani, Lucy A. Godley, Debra M. Bensen-Kennedy, Karen W.L. Yee, Gunnar Juliusson, Farhad Ravandi, Amelia Langston, Arnon Nagler, Alexander E. Perl, Richard Stone, Stephen H. Petersdorf, Mark J. Levis, and Eunice S. Wang
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Salvage therapy ,Biochemistry ,law.invention ,Randomized controlled trial ,law ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Survival analysis ,Chemotherapy ,business.industry ,Lestaurtinib ,Myeloid leukemia ,Cell Biology ,Hematology ,Surgery ,Tolerability ,embryonic structures ,Fms-Like Tyrosine Kinase 3 ,business ,Settore MED/15 - Malattie del Sangue ,medicine.drug - Abstract
In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily. Endpoints included complete remission or complete remission with incomplete platelet recovery (CR/CRp), overall survival, safety, and tolerability. Correlative studies included pharmacokinetics and analysis of in vivo FLT3 inhibition. There were 29 patients with CR/CRp in the lestaurtinib arm and 23 in the control arm (26% vs 21%; P = .35), and no difference in overall survival between the 2 arms. There was evidence of toxicity in the lestaurtinib-treated patients, particularly those with plasma levels in excess of 20μM. In the lestaurtinib arm, FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achieved in only 58% of patients receiving lestaurtinib. Given that such a small proportion of patients on this trial achieved sustained FLT3 inhibition in vivo, any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited. Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients with FLT3 mutant acute myeloid leukemia in first relapse. This study is registered at www.clinicaltrials.gov as #NCT00079482.
- Published
- 2011
16. Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
- Author
-
Paul J. Shami, Stefan Faderl, Andrew M. Yeager, Roger M. Lyons, Michael B. Maris, Dan Douer, Stephen H. Petersdorf, Janice Gabrilove, Tibor Kovascovics, Stephen Eckert, Hagop M. Kantarjian, Martha Arellano, Rekha Abichandani, Harry P. Erba, David F. Claxton, and Michael Craig
- Subjects
Cancer Research ,medicine.medical_specialty ,Performance status ,business.industry ,Nausea ,Phases of clinical research ,medicine.disease ,Gastroenterology ,Rash ,Surgery ,Oncology ,Internal medicine ,medicine ,Clofarabine ,medicine.symptom ,business ,Prospective cohort study ,Survival rate ,Febrile neutropenia ,medicine.drug - Abstract
Purpose This phase II study assessed clofarabine monotherapy in older adults (≥ 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. Patients and Methods Clofarabine was administered intravenously for 5 days at 30 mg/m2/d during induction and 20 mg/m2/d during reinduction/consolidation (six cycles maximum). The primary end point was overall remission rate (ORR; ie, complete remission [CR] plus CR with incomplete platelet recovery [CRp]). Results In 112 evaluable patients who were treated (median age, 71 years; range, 60 to 88 years), the ORR was 46% (38% CR, 8% CRp). ORR by unfavorable prognostic factor was 39% for patients ≥ 70 years of age; 32% for Eastern Cooperative Oncology Group (ECOG) performance status 2; 51% for antecedent hematologic disorder; 54% for intermediate karyotype; 42% for unfavorable karyotype; and 48%, 51%, and 38% for one, two, and three risk factors, respectively. The median disease-free survival was 37 weeks (95% CI, 26 to 56 weeks). Median duration of remission was 56 weeks (95% CI, 33 to not estimable). The estimated median overall survival was 41 weeks (95% CI, 28 to 53 weeks) for all patients, 59 weeks for patients with CR/CRp, and 72 weeks for patients with CR. The 30-day all-cause mortality was 9.8%. The most common non-laboratory drug-related toxicities (≥ 20% patients) were nausea, febrile neutropenia, vomiting, diarrhea, rash, and fatigue. Conclusion Clofarabine is an active agent with acceptable toxicity in patients age 60 years or older with untreated AML who have at least one unfavorable prognostic factor. ORR did not seem affected by the presence of multiple unfavorable prognostic factors.
- Published
- 2010
17. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia
- Author
-
Pamela S. Becker, Kenneth J. Kopecky, Derek L. Stirewalt, Sylvia Chien, Frederick R. Appelbaum, Thalia Papayannopoulou, Cheryl L. Willman, John M. Harlan, Stephen H. Petersdorf, and Adrianne N. Wilks
- Subjects
Adult ,Male ,Myeloid ,Adolescent ,medicine.medical_treatment ,Immunology ,Vascular Cell Adhesion Molecule-1 ,Antineoplastic Agents ,Integrin alpha4beta1 ,Biology ,Biochemistry ,Cell Line, Tumor ,hemic and lymphatic diseases ,Cell Adhesion ,medicine ,Humans ,Granulocyte Precursor Cells ,Survival rate ,Aged ,Aged, 80 and over ,Chemotherapy ,Myeloid Neoplasia ,Myeloid leukemia ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Chemotherapy regimen ,Peptide Fragments ,Recombinant Proteins ,Fibronectins ,Gene Expression Regulation, Neoplastic ,Survival Rate ,Leukemia, Myeloid, Acute ,Leukemia ,Treatment Outcome ,medicine.anatomical_structure ,Cancer research ,Cytarabine ,Cytokines ,Female ,Bone marrow ,Protein Binding ,medicine.drug - Abstract
Adhesion of acute myeloid leukemia (AML) blasts in the bone marrow microenvironment confers protection from chemotherapy-induced apoptosis. One mechanism for retention of blasts within the bone marrow is adhesion via very late antigen-4 (VLA-4), the α4β1 integrin heterodimer that binds to its main ligands, fibronectin, and vascular cell adhesion molecule-1 (VCAM-1). To examine the relationship of functional expression of VLA-4 to prognosis in AML, we studied marrow samples from 175 adult AML patients who underwent induction chemotherapy with anthracycline and cytarabine on Southwest Oncology Group trials. The studies included flow cytometry and functional in vitro assays for ligand binding and maximal β1 activation. VLA-4 expression varied widely, with mean expression 60.6% for α4, and was not significantly associated with response to chemotherapy, relapse-free, or overall survival (OS). However, increased binding of soluble VCAM-1 via VLA-4 was significantly associated with longer OS, corrected for age (P = .033). Estimated 5-year OS was 31% (95% confidence interval, 14%-48%) in 30 patients with soluble VCAM-1 binding greater than or equal to 40%, compared with 10% (confidence interval, 3%-17%) in 72 patients with lower binding. Adhesion and migratory properties of AML blasts thus appear to influence chemosensitivity and therefore may be therapeutic targets.
- Published
- 2009
18. External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma
- Author
-
Elisabeth J. Rushing, Cathryn Rankin, Robert B. Livingston, Deborah T. Blumenthal, Saul E. Rivkin, Alexander M. Spence, Mitchel S. Berger, Harmon J. Eyre, Allen Cohn, Keith J. Stelzer, and Stephen H. Petersdorf
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Southwestern United States ,Humans ,Medicine ,Survival analysis ,Aged ,Neoplasm Staging ,Cisplatin ,Carmustine ,Chemotherapy ,Brain Neoplasms ,business.industry ,Glioma ,Middle Aged ,Evaluable Disease ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Nitrogen mustard ,Radiation therapy ,Treatment Outcome ,chemistry ,Female ,Radiotherapy, Conformal ,business ,Progressive disease ,medicine.drug - Abstract
BACKGROUND. The poor prognosis reported for patients with high‒grade glial neoplasms indicates a need for the development of multimodality therapeutic approaches. The addition of chemotherapy has contributed variably to increased survival. The objective of the current study (Southwest Oncology Group [SWOG] 9016) was to determine whether concurrent radiotherapy and chemotherapy with the combination of carmustine and cisplatin could be given safely in a cooperative group setting. Additional objectives included the estimation of response rate, the rate of disease stabilization, and the probability of 1-year survival. METHODS. SWOG 9016 study included 59 eligible patients with grade III or IV astrocytoma who received radiotherapy concurrently with carmustine/cisplatin chemotherapy. Patients were required to have either measurable or evaluable disease. The therapeutic endpoints were comprised of complete response (CR), partial response (PR), or progressive disease (PD). RESULTS. Six patients achieved a CR (CR rate of 10%; 95% confidence interval [95% CI], 4–21%), 4 achieved a PR (PR rate of 7%; 95% CI, 2–16%), and 2 patients (3%) experienced an unconfirmed response. Twenty-four patients (41%; 95% CI, 28–54%) had stable disease and 10 patients (17%) demonstrated PD. The overall disease stabilization rate (CR + PR + stable disease, excluding unconfirmed response) was 58% (95% CI, 44–70%). CONCLUSIONS. Despite the presence of a cohort of long‒term survivors, the results of the current study do not appear to support the additional studyor routine use of concurrent cisplatin and carmustine. Cancer 2008. © 2008 American Cancer Society.
- Published
- 2008
19. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma
- Author
-
Nathan Crawford, Ajay K. Gopal, Oliver W. Press, David G. Maloney, John M. Pagel, Brian G. Till, Stephen H. Petersdorf, William I. Bensinger, Leona Holmberg, and Ted Gooley
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Lymphoma, Mantle-Cell ,Hematopoietic stem cell transplantation ,CHOP ,Transplantation, Autologous ,Dexamethasone ,Disease-Free Survival ,Antibodies, Monoclonal, Murine-Derived ,Autologous stem-cell transplantation ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Cyclophosphamide ,Survival rate ,Aged ,business.industry ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Antibodies, Monoclonal ,Induction chemotherapy ,Hematology ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Surgery ,Survival Rate ,Transplantation ,Regimen ,Doxorubicin ,Vincristine ,Prednisone ,Female ,Mantle cell lymphoma ,Neoplasm Recurrence, Local ,Rituximab ,business - Abstract
We analysed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received induction chemotherapy with HyperCVAD with or without rituximab (+/-R) followed by ASCT in first complete or partial remission (CR1/PR1), 15 received CHOP (+/-R) followed by ASCT in CR1/PR1 and 20 received ASCT following disease progression. Estimates of overall and progression-free survival (PFS) at 3 years among patients transplanted in CR1/PR1 were 93% and 63% compared with 46% and 36% for patients transplanted with relapsed/refractory disease, respectively. The hazard of mortality among patients transplanted with relapsed/refractory disease was 6.09 times that of patients transplanted in CR1/PR1 (P = 0.006). Patients in the CHOP (+/-R) group had a higher risk of failure for PFS compared with patients in the HyperCVAD (+/-R) group, though the difference did not reach statistical significance (hazard ratio 3.67, P = 0.11). These results suggest that ASCT in CR1/PR1 leads to improved survival outcomes for patients with MCL compared to ASCT with relapsed/refractory disease, and a HyperCVAD (+/-R) induction regimen may be associated with an improved PFS among patients transplanted in CR1/PR1.
- Published
- 2008
20. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500)
- Author
-
Cathryn Rankin, Stanley P. Balcerzak, Shaker R. Dakhil, Howard R. Terebelo, Frederick R. Appelbaum, Cheryl L. Willman, Anand B. Karnad, Stephen H. Petersdorf, and David R. Head
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Time Factors ,Anthracycline ,medicine.drug_class ,Daunorubicin ,Antimetabolite ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Ethnicity ,medicine ,Humans ,Hematology ,business.industry ,Cytarabine ,Myeloid leukemia ,Middle Aged ,Survival Analysis ,United States ,Confidence interval ,Leukemia, Myeloid, Acute ,Regimen ,Treatment Outcome ,Female ,business ,medicine.drug - Abstract
Induction therapy for acute myeloid leukemia (AML) usually consists of 7 days of cytarabine at 100–200 mg/m2/day and an anthracycline. Such combinations produce complete response (CR) rates of 60–80% in patients with de novo AML. On the basis of a previous report, suggesting a higher CR rate using a regimen of standard daunomycin and cytarabine followed by 3 days of high-dose cytarabine (HDAC), 101 eligible patients received this regimen in a phase II trial. Sixty patients [59%, 95% confidence interval (CI) 49–69%] achieved a CR, and 10 patients died of infection during induction. Although cytogenetic risk group affected overall survival (P = 0.0016) and relapse-free survival (P = 0.0043), it had no impact on CR rate (P = 0.63). Patients received postremission therapy with repetitive courses of alternate day high-dose cytarabine; this was associated with considerable toxicity and the majority of patients could not receive all of the scheduled postremission therapy. The estimated median survival was 23 months (95% CI 15–34 months), and the estimated probability of surviving 5 years was 34% (95% CI 24–43%). The results of this intensive induction regimen were similar to that seen in previous trials and were not as promising as reported in the previous pilot study. Am. J. Hematol., 2007. © 2007 Wiley-Liss, Inc.
- Published
- 2007
21. A model for prediction ofFLT3-ITD andNPM1(withoutFLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia
- Author
-
Megan Othus, Fabiana Ostronoff, Paul C. Hendrie, Roland B. Walter, Stefan Faderl, Soheil Meshinchi, Stephen H. Petersdorf, Sherry Pierce, Pamela S. Becker, Alan F. List, Frederick R. Appelbaum, Cheryl L. Willman, Farhad Ravandi, John M. Pagel, John E. Godwin, Ravinder K Sandhu, Elihu H. Estey, Hagop M. Kantarjian, Jorge E. Cortes, and Derek L. Stirewalt
- Subjects
Oncology ,medicine.medical_specialty ,NPM1 ,Article ,Gene Duplication ,hemic and lymphatic diseases ,Internal medicine ,Gene duplication ,medicine ,Humans ,In patient ,neoplasms ,Nucleophosmin ,Models, Statistical ,business.industry ,Cytogenetics ,Nuclear Proteins ,Hematology ,Prognosis ,body regions ,Leukemia, Myeloid, Acute ,fms-Like Tyrosine Kinase 3 ,Tandem Repeat Sequences ,embryonic structures ,Fms-Like Tyrosine Kinase 3 ,Immunology ,Myeloid leukaemia ,business ,psychological phenomena and processes ,Flt3 itd - Abstract
Acute myeloid leukaemia (AML) varies greatly in response to therapy. Although cytogenetics is the most important predictor of response, it is least informative in the 40 - 50% of adults with normal cytogenetics (Grimwade et al, 1998). However, an increasing number of molecular markers with prognostic significance, particularly in cytogenetically normal AML (CN-AML), have been identified. The two most common are internal tandem duplications (ITD) in the FLT3 gene (FLT3-ITD) and mutations in the nucleophosmin gene (NPM1) with frequencies of approximately 50% and 30%, respectively, in CN-AML. While FLT3-ITD is associated with short relapse-free and overall survival, the prognosis of CN-AML with NPM1 mutations without FLT3-ITD (NPM+/FLT3-ITD-) is similar to that of “favourable” cytogenetics AML (Kottaridis et al, 2001;Schnittger et al, 2005; Thiede et al 2006).
- Published
- 2013
22. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis
- Author
-
Irwin D. Bernstein, Oliver W. Press, Frederick R. Appelbaum, David G. Maloney, Joseph G. Rajendran, Paul J. Martin, Janet F. Eary, Lawrence D. Durack, Dana C. Matthews, Stephen H. Petersdorf, Jane Golden, Ajay K. Gopal, Sharon A. Bush, and Ted Gooley
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Follicular lymphoma ,Hematopoietic stem cell transplantation ,Biochemistry ,Gastroenterology ,Tositumomab ,Cohort Studies ,Iodine Radioisotopes ,Internal medicine ,Humans ,Medicine ,Lymphoma, Follicular ,Chemotherapy ,business.industry ,Lymphoma, Non-Hodgkin ,Hazard ratio ,Hematopoietic Stem Cell Transplantation ,Dose-Response Relationship, Radiation ,Cell Biology ,Hematology ,Middle Aged ,Radioimmunotherapy ,Total body irradiation ,Antigens, CD20 ,medicine.disease ,Combined Modality Therapy ,Surgery ,Survival Rate ,Radiation therapy ,Treatment Outcome ,Multivariate Analysis ,Disease Progression ,Female ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
We performed a multivariable comparison of 125 consecutive patients with follicular lymphoma (FL) treated at our centers with either high-dose radioimmunotherapy (HD-RIT) using 131I-anti-CD20 (n = 27) or conventional high-dose therapy (C-HDT) (n = 98) and autologous hematopoietic stem cell transplantation. The groups were similar, although more patients treated with HD-RIT had an elevated pretransplantation level of lactate dehydrogenase (41% versus 20%, P = .03) and elevated international prognostic score (41% versus 19%, P = .02). Patients treated with HD-RIT received individualized therapeutic doses of 131I-tositumomab (median, 19.7 GBq [531 mCi]) to deliver 17 to 31 Gy (median, 27 Gy) to critical organs. Patients treated with C-HDT received total body irradiation plus chemotherapy (70%) or chemotherapy alone (30%). Patients treated with HD-RIT experienced improved overall survival (OS) (unadjusted hazard ratio [HR] for death = 0.4 [95% confidence interval (95% CI), 0.2-0.9], P = .02; adjusted HR, 0.3, P = .004) and progression-free survival (PFS) (unadjusted HR = .6 [95% C.I., 0.3-1.0], P = .06; adjusted HR, 0.5, P = .03) versus patients treated with C-HDT. The estimated 5-year OS and PFS were 67% and 48%, respectively, for HD-RIT and 53% and 29%, respectively, for C-HDT. One hundred-day treatment-related mortality was 3.7% in the HD-RIT group and 11% in the C-HDT group. The probability of secondary myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) was estimated to be .076 at 8 years in the HD-RIT group and .086 at 7 years in the C-HDT group. HD-RIT may improve outcomes versus C-HDT in patients with relapsed FL. (Blood. 2003;102:2351-2357)
- Published
- 2003
23. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen
- Author
-
William I. Bensinger, Oliver W. Press, Leona Holmberg, H. Hooper, David G. Maloney, F R Appelbaum, F. Gutierrez-Delgado, T. Chauncey, Richard T. Maziarz, and Stephen H. Petersdorf
- Subjects
Adult ,Male ,Melphalan ,Oncology ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,ThioTEPA ,Transplantation, Autologous ,Autologous stem-cell transplantation ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Mucositis ,Humans ,Medicine ,Busulfan ,Retrospective Studies ,Salvage Therapy ,Transplantation ,Chemotherapy ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Total body irradiation ,Prognosis ,medicine.disease ,Hodgkin Disease ,Survival Analysis ,Surgery ,Regimen ,Treatment Outcome ,Female ,business ,Thiotepa ,Whole-Body Irradiation ,medicine.drug - Abstract
We evaluated prognostic factors and treatment outcome of patients with relapsed/refractory Hodgkin's disease (HD) receiving autologous stem cell transplantation (ASCT). In total, 92 patients received total body irradiation, cyclophosphamide and etoposide (TBI/CY/E) (n=42) or busulfan, melphalan and thiotepa (Bu/Mel/T) (n=50) supported with ASCT. A total of 33 (66%) patients receiving the Bu/Mel/T regimen had a prior history of dose-limiting irradiation. Mucositis, hepatic and pulmonary toxicities were the main causes of morbidity and mortality, irrespective of the conditioning regimen. The transplant-related mortality was 15%. With a median follow-up of 6 years (range 2.5-11), the cumulative probabilities of survival, event-free survival (EFS) and relapse at 6 years were 55, 51 and 32%. The 6-year Kaplan-Meier (KM) probabilities of EFS for patients with less advanced disease (patients in first chemotherapy-responsive relapse or second remission (n=42)) and more advanced disease (all other patients (n=50)) were 60 and 44%. No differences in toxicities and efficacy between the conditioning regimens were found. ASCT is an effective treatment for patients with refractory/relapsed HD. Female patients and patients with less advanced disease at transplant had a better outcome. Patients with prior irradiation benefited from the Bu/Mel/T regimen.
- Published
- 2003
24. Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine
- Author
-
Amy R. McQuary, Randall W. Knoebel, Eli Estey, Paul C. Hendrie, Pamela S. Becker, Stephen H. Petersdorf, and Frederick R. Appelbaum
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Adenine Nucleotides ,business.industry ,Cytarabine ,Myeloid leukemia ,Hematology ,Clofarabine/Cytarabine ,Infections ,Leukemia, Myeloid, Acute ,Refractory ,Drug Resistance, Neoplasm ,Recurrence ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Arabinonucleosides ,Treatment Failure ,business ,Clofarabine - Published
- 2011
25. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report
- Author
-
Todd A. Alonzo, Alan S. Gamis, Susana C. Raimondi, Megan Othus, Betsy A. Hirsch, Michael R. Loken, Fabiana Ostronoff, Soheil Meshinchi, Beverly J. Lange, Stephen H. Petersdorf, Frederick R. Appelbaum, Jerald P. Radich, and Robert B. Gerbing
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Pediatrics ,Myeloid ,Neoplasm, Residual ,Adolescent ,Oncogene Proteins, Fusion ,Immunology ,Context (language use) ,Kaplan-Meier Estimate ,Biochemistry ,Young Adult ,Age Distribution ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Treatment Failure ,Young adult ,Child ,business.industry ,Remission Induction ,Infant, Newborn ,Cancer ,Infant ,hemic and immune systems ,Cell Biology ,Hematology ,Impedance threshold device ,medicine.disease ,body regions ,Leukemia ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,fms-Like Tyrosine Kinase 3 ,Concomitant ,Child, Preschool ,embryonic structures ,Fms-Like Tyrosine Kinase 3 ,Multivariate Analysis ,Regression Analysis ,Female ,business ,psychological phenomena and processes - Abstract
NUP98/NSD1 has recently been reported in association with poor outcome in acute myeloid leukemia (AML). Previous studies also observed a high overlap between NUP98/NSD1 and FLT3/ITD, raising the question as to whether the reported poor outcome is due to NUP98/NSD1 or caused by the co-occurrence of these 2 genetic lesions. We aimed to determine the prognostic significance of NUP98/NSD1 in the context of FLT3/ITD AML. A total of 1421 patients enrolled in 5 consecutive Children's Oncology Group/Children's Cancer Group and SWOG trials were evaluated. NUP98/NSD1 was found in 15% of FLT3/ITD and 7% of cytogenetically normal (CN)-AML. Those with dual FLT3/ITD and NUP98/NSD1 (82% of NUP98/NSD1 patients) had a complete remission rate of 27% vs 69% in FLT3/ITD without NUP98/NSD1 (P < .001). The corresponding 3-year overall survival was 31% vs 48% (P = .011), respectively. In CN-AML, patients with concomitant NUP98/NSD1 and FLT3/ITD had a worse outcome than those harboring NUP98/NSD1 only. In multivariate analysis, the dual NUP98/NSD1 and FLT3/ITD remained an independent predictor of poor outcome, and NUP98/NSD1 without FLT3/ITD lost its prognostic significance. Our study demonstrates that it is the interaction between NUP98/NSD1 and FLT3/ITD that determines the poor outcome of patients with NUP98/NSD1 disease.
- Published
- 2014
26. A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
- Author
-
Darrell R. Fisher, Janet F. Eary, Sharon A. Bush, Stephen Liu, Frederick R. Appelbaum, Irwin D. Bernstein, Oliver W. Press, Ajay K. Gopal, Justin P. Smith, James W. Borrow, David G. Maloney, Stephen H. Petersdorf, Dana C. Matthews, Paul J. Martin, Ted Gooley, Bruce A. Porter, Brent L. Wood, Lawrence D. Durack, and Joseph G. Rajendran
- Subjects
medicine.medical_specialty ,Chemotherapy ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,Immunology ,Urology ,Cell Biology ,Hematology ,Biochemistry ,Tositumomab ,Surgery ,Transplantation ,Radiation therapy ,Autologous stem-cell transplantation ,Radioimmunotherapy ,Medicine ,business ,Etoposide ,medicine.drug - Abstract
Relapsed B-cell lymphomas are incurable with conventional chemotherapy and radiation therapy, although a fraction of patients can be cured with high-dose chemoradiotherapy and autologous stem-cell transplantation (ASCT). We conducted a phase I/II trial to estimate the maximum tolerated dose (MTD) of iodine 131 (131I)–tositumomab (anti-CD20 antibody) that could be combined with etoposide and cyclophosphamide followed by ASCT in patients with relapsed B-cell lymphomas. Fifty-two patients received a trace-labeled infusion of 1.7 mg/kg 131I-tositumomab (185-370 MBq) followed by serial quantitative gamma-camera imaging and estimation of absorbed doses of radiation to tumor sites and normal organs. Ten days later, patients received a therapeutic infusion of 1.7 mg/kg tositumomab labeled with an amount of131I calculated to deliver the target dose of radiation (20-27 Gy) to critical normal organs (liver, kidneys, and lungs). Patients were maintained in radiation isolation until their total-body radioactivity was less than 0.07 mSv/h at 1 m. They were then given etoposide and cyclophosphamide followed by ASCT. The MTD of131I-tositumomab that could be safely combined with 60 mg/kg etoposide and 100 mg/kg cyclophosphamide delivered 25 Gy to critical normal organs. The estimated overall survival (OS) and progression-free survival (PFS) of all treated patients at 2 years was 83% and 68%, respectively. These findings compare favorably with those in a nonrandomized control group of patients who underwent transplantation, external-beam total-body irradiation, and etoposide and cyclophosphamide therapy during the same period (OS of 53% and PFS of 36% at 2 years), even after adjustment for confounding variables in a multivariable analysis.
- Published
- 2000
27. Lymphoproliferative Disorders Presenting as Mediastinal Neoplasms
- Author
-
Stephen H. Petersdorf and Douglas E. Wood
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pathology ,Lymphoma ,Lymphoproliferative disorders ,Mediastinal Neoplasms ,immune system diseases ,hemic and lymphatic diseases ,Humans ,Medicine ,Neoplasm Staging ,Superior vena cava syndrome ,business.industry ,Lymphoblastic lymphoma ,Large-cell lymphoma ,Mediastinum ,General Medicine ,respiratory system ,medicine.disease ,Mediastinal Neoplasm ,respiratory tract diseases ,Non-Hodgkin's lymphoma ,surgical procedures, operative ,medicine.anatomical_structure ,Surgery ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
Lymphoproliferative disorders may present in any organ of the body. The mediastinum is an uncommon location for presentation of these heterogeneous disorders, but involvement of the mediastinum may be the sole site of disease for several aggressive lymphomas. Both Hodgkin's disease and non-Hodgkin's lymphoma may present in the mediastinum. The most common types of non-Hodgkin's lymphoma involving the mediastinum include lymphoblastic lymphoma and mediastinal large cell lymphoma. These lymphomas most commonly develop in the anterior mediastinum but may be seen in the middle and posterior mediastinum. Symptoms associated with a mediastinal presentation of a lymphoproliferative disorder are often attributable to compression of mediastinal structures (eg, superior vena cava syndrome) or invasion of thoracic structures such as the pericardium or pleura. Although staging can be performed with routine imaging studies, surgical intervention is often required to ensure accurate histologic diagnosis of these lymphomas. Once a diagnosis has been established, therapeutic modalities usually include chemotherapy and/or radiotherapy.
- Published
- 2000
28. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617
- Author
-
Thomas R. Chauncey, David R. Head, Frederick R. Appelbaum, Cheryl L. Willman, Frederick W Luthardt, Matt Kalaycio, Eric H. Kraut, Muhammad Shurafa, Dennis F. Moore, Stephen H. Petersdorf, Cathryn Rankin, Catherine P. Leith, Kenneth J. Kopecky, John E. Godwin, I-Ming Chen, and Jeanne E. Anderson
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Population ,Cyclosporins ,Antimetabolite ,Disease-Free Survival ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,education ,Etoposide ,Aged ,Mitoxantrone ,education.field_of_study ,Chemotherapy ,business.industry ,Induction chemotherapy ,Hematology ,Middle Aged ,medicine.disease ,Survival Analysis ,Regimen ,Leukemia ,Treatment Outcome ,Leukemia, Myeloid ,Acute Disease ,Female ,business ,medicine.drug - Abstract
Older patients with acute myelogenous leukemia (AML) have overexpression of P-glycoprotein (Pgp+), and this has been shown to correlate quantitatively with therapeutic outcome. Since Pgp-mediated efflux of cytotoxic drugs can be inhibited by the cyclosporine analogue, PSC 833, we investigated the use of this agent with a 5-day mitoxantrone/etoposide regimen in patients over age 55 with newly diagnosed AML. Previous studies suggested a 33% incidence of grade IV/V non-hematologic toxicity with the use of mitoxantrone 10 mg/M(2) and etoposide 100 mg/M(2), each for 5 days, in this patient population. Since PSC 833 alters the pharmacokinetic excretion of MDR-related cytotoxins, this phase I dose-finding study was performed to identify doses of mitoxantrone/etoposide associated with a similar 33% incidence of grade IV/V non-hematologic toxicity, when given with PSC 833. Mitoxantrone/etoposide (M/E) doses were escalated in fixed ratio from a starting dose of M: 4 mg/M(2) and E: 40 mg/M(2), to M: 7 mg/M(2) and E: 70 mg/M(2), in successive cohorts of eight patients each. PSC 833 was well tolerated and the MTD of this M/E regimen with PSC 833 in this population was M: 6 mg/M(2) and E: 60 mg/M(2). The complete response (CR) rate for all patients was 50% (15/30) and was considerably higher for de novo than for secondary AML. These data suggest that the addition of PSC 833 to an M/E regimen for older patients with untreated AML is well tolerated but requires a reduction in M/E dosing to avoid increased toxicity.
- Published
- 2000
29. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study
- Author
-
FR Appelbaum, Thomas R. Chauncey, A York, Stephen H. Petersdorf, John A. Thompson, Oliver W. Press, William I. Bensinger, Nanette Robinson, Catherine G. Lindgren, Buckner Cd, A Fefer, and M. Benyunes
- Subjects
Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,medicine.medical_treatment ,Phases of clinical research ,Hematopoietic stem cell transplantation ,Gastroenterology ,Article ,autologous BMT ,Autologous stem-cell transplantation ,Adjuvants, Immunologic ,Internal medicine ,medicine ,Humans ,Child ,Multiple myeloma ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,Infant ,Hematology ,Middle Aged ,medicine.disease ,Minimal residual disease ,Combined Modality Therapy ,Surgery ,Lymphoma ,Clinical trial ,Regimen ,Child, Preschool ,Hematologic Neoplasms ,Interleukin-2 ,Female ,immunotherapy ,business ,PBSC - Abstract
The success of autologous stem cell transplantation (ASCT) for hematologic malignancy is limited largely by a high relapse rate. It is postulated that IL-2 administered after ASCT may eliminate minimal residual disease and thereby reduce relapses. A phase I/II study was performed to identify a regimen of IL-2 (Chiron) that could be given early after ASCT in phase III trials. In the phase I study, beginning a median of 46 days after ASCT for hematologic malignancy, cohorts of three to four patients received escalating doses of 'induction' IL-2 of 9, 10, or 12 x 10(6) IU/m2/day for 4 or 5 days by continuous i.v. infusion (CIV), followed by a 4-day rest period, and then 1.6 x 10(6) IU/m2/day of maintenance IL-2 by CIV for 10 days. The maximum tolerated dose (MTD) of induction IL-2 was 9 x 10(6) IU/m2/day x 4. In the phase II study, 52 patients received the MTD. Eighty percent of patients completed induction IL-2. Most patients exhibited some degree of capillary leak. One patient died of CMV pneumonia and one died of ARDS. Maintenance IL-2 was well tolerated. In the phase I/II study, 16 of 31 patients with non-Hodgkin lymphoma (NHL), 3/8 with Hodgkin disease (HD), 4/17 with AML, and 4/5 with ALL remain in CR. Two of six multiple myeloma (MM) patients remain in PR. Although the regimen of IL-2 identified had significant side-effects in some patients, it was well tolerated in the majority of patients. Phase III prospectively randomized clinical trials are in progress to determine if this IL-2 regimen will decrease the relapse rate after ASCT for AML and NHL.
- Published
- 1997
30. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer
- Author
-
Leona Holmberg, Buckner Cd, Paul L. Weiden, P. Montgomery, R McCroskey, J Klarnet, R. T. Maziarz, K Lilleby, F R Appelbaum, Saul E. Rivkin, C H Weaver, Stephen H. Petersdorf, A Hertler, W Nichols, E Ellis, Kathy Schiffman, S Rowley, and William I. Bensinger
- Subjects
Adult ,Melphalan ,medicine.medical_specialty ,medicine.medical_treatment ,Drug Resistance ,Breast Neoplasms ,ThioTEPA ,Transplantation, Autologous ,Gastroenterology ,Breast cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Busulfan ,Survival rate ,Aged ,Transplantation ,Chemotherapy ,business.industry ,Graft Survival ,Hematopoietic Stem Cell Transplantation ,Cancer ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Metastatic breast cancer ,Surgery ,Survival Rate ,Female ,business ,Thiotepa ,medicine.drug - Abstract
The purpose of this study was to determine the outcome of patients with metastatic breast cancer treated with high-dose busulfan (Bu), melphalan (Mel) and thiotepa (TT) followed by peripheral blood stem cell (PBSC) infusion. Fifty-one patients with chemotherapy refractory (n = 32) or responsive (n = 19) metastatic breast cancer received Bu (12 mg/kg), Mel (100 mg/m2) and TT (500 mg/m2) followed by PBSC collected after chemotherapy and growth factor (n = 43) or growth factor alone (n = 8). The 100 day treatment-related mortality was 8% including one death from cytomegalovirus pneumonia, one from aspiration pneumonia and two from regimen-related toxicity (RRT). Seven of 28 refractory (25%) and 5/7 (71%) responsive patients with evaluable disease achieved a complete response of all measurable disease or all soft tissue disease with at least improvement in bone lesions (PR*). Fifteen of 51 patients (29%) are alive and progression-free a median of 423 days (range 353-934) after treatment, 5/32 (16%) with refractory disease and 10/19 (53%) with responsive disease. The probabilities of progression-free survival (PFS) at 1.5 years for the patients with refractory (n = 32) and responsive (n = 19) disease were 0.24 and 0.53, respectively. These preliminary data suggest that high-dose Bu/Mel/TT has significant activity in patients with advanced breast cancer and may be superior to some previously published regimens.
- Published
- 1997
31. Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission
- Author
-
Elihu H. Estey, Kathleen Shannon Dorcy, Vicky Sandhu, Mohamed L. Sorror, Pamela S. Becker, Brenda M. Sandmaier, Ted Gooley, Raya Mawad, Paul O'Donnell, Frederick R. Appelbaum, Stephen H. Petersdorf, Jack M. Lionberger, Bart L. Scott, Paul C. Hendrie, Roland B. Walter, H. Joachim Deeg, and John M. Pagel
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Myeloid ,Adolescent ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Gastroenterology ,Young Adult ,Risk Factors ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Transplantation, Homologous ,Humans ,Young adult ,Aged ,Hematopoietic cell ,business.industry ,Remission Induction ,Complete remission ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,ORIGINAL REPORTS ,Middle Aged ,medicine.disease ,Surgery ,Transplantation ,Leukemia ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Oncology ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Purpose To determine the frequency of allogeneic hematopoietic cell transplantation (HCT) for patients with acute myeloid leukemia (AML) in first complete remission (CR1). Patients and Methods Between January 1, 2008, and March 1, 2011, 212 newly diagnosed patients with AML received treatment at our center. Ninety-five patients age less than 75 years with intermediate- or high-risk AML achieved a complete remission, and 21 patients achieved a morphologic remission with incomplete blood count recovery. Results Seventy-eight (67%; 95% CI, 58% to 76%) of 116 patients received HCT at a median of 2.8 months (range, 0.5 to 19 months) from their CR1 date. The median age was 57 years in both the HCT patient group (range, 18 to 75 years) and the non-HCT patient group (range, 24 to 70 years; P = .514). Between the HCT patients and the non-HCT patients, the mean Eastern Cooperative Oncology Group performance status was 1.1 compared with 1.5, respectively (P = .005), and the average HCT comorbidity score within 60 days of CR1 was 1.7 and 2.1, respectively (P = .68). Twenty-nine (76%) of 38 non-HCT patients were HLA typed, and matched donors were found for 13 of these 29 patients (34% of all non-HCT patients). The most common causes for patients not receiving transplantation in CR1 were early relapse (within 6 months) in 12 patients (32%), poor performance status in eight patients (21%), and physician decision in five patients (13%). Conclusion HCT can be performed in CR1 in the majority of patients with AML for whom it is currently recommended. The main barriers to HCT were early relapse and poor performance status, highlighting the need for improved therapies for patients with AML of all ages.
- Published
- 2013
32. Acute lymphoblastic leukemia
- Author
-
Joseph C. Alvarnas, Salil Goorha, Jennifer Cultrera, Stephanie A. Terezakis, Kristina M. Gregory, Geoffrey L. Uy, Patrick A. Brown, Peter F. Coccia, Hetty E. Carraway, Naresh Bellam, Daniel J. DeAngelo, Michael Millenson, William Blum, Stephen H. Petersdorf, Andrew D. Zelenetz, Olga Frankfurt, Karen K. Ballen, Susan O'Brien, Michael Boyer, Haydar Frangoul, Meir Wetzler, Maoko Naganuma, Dan Douer, Lloyd E. Damon, Arati V. Rao, Patricia Aoun, and Steven Coutre
- Subjects
Oncology ,medicine.medical_specialty ,Neoplasm, Residual ,business.industry ,Lymphoblastic Leukemia ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Clinical Practice ,Risk Factors ,Internal medicine ,Medicine ,Humans ,Philadelphia Chromosome ,business - Abstract
The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations. It is recommended that patients be treated at specialized centers with expertise in the management of ALL.
- Published
- 2012
33. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report
- Author
-
Soheil Meshinchi, Daniel E. Geraghty, Jerald P. Radich, Cheryl L. Willman, Matthew A. Kutny, Phoenix A. Ho, Derek L. Stirewalt, Stephen H. Petersdorf, John E. Godwin, Frederick R. Appelbaum, Megan Othus, and Fabiana Ostronoff
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Myeloid ,Biology ,Article ,DNA Methyltransferase 3A ,Exon ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,DNA (Cytosine-5-)-Methyltransferases ,Survival rate ,Etoposide ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Mitoxantrone ,Daunorubicin ,Cytarabine ,Myeloid leukemia ,Hematology ,Exons ,Middle Aged ,medicine.disease ,Prognosis ,Survival Rate ,Leukemia ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,embryonic structures ,Mutation ,Cancer research ,Female ,medicine.drug ,Follow-Up Studies - Abstract
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report
- Published
- 2012
34. New Treatment Approaches for Older Adults with Multiple Myeloma
- Author
-
Ravi Vij, Stephen H. Petersdorf, Arti Hurria, Bruno C. Medeiros, and Tanya M. Wildes
- Subjects
Oncology ,Melphalan ,medicine.medical_specialty ,Chemotherapy ,education.field_of_study ,business.industry ,Bortezomib ,medicine.medical_treatment ,Population ,medicine.disease ,Article ,Thalidomide ,Prednisone ,Internal medicine ,medicine ,Geriatrics and Gerontology ,business ,education ,Multiple myeloma ,Lenalidomide ,medicine.drug - Abstract
The incidence of multiple myeloma (MM) increases with age, and with the aging of the population, the number of adults with MM is expected to double in the next 20 years. Novel agents, including the immunomodulatory agents thalidomide and lenalidomide, and the proteosome inhibitor bortezomib have dramatically changed the treatment of multiple myeloma in the past decade. The purpose of this review was to examine the recent clinical therapeutic trials in older adults with MM. A number of trials have evaluated the addition of novel agents to the traditional backbone of melphalan and prednisone. The combination of thalidomide with melphalan and prednisone has been evaluated in 7 randomized trials. The combination improves response rates and, in meta-analyses, survival, but at the expense of increased toxicity. Other combination regimens which include lenalidomide or bortezomib likewise are associated with higher response rates, but at the expense of greater toxicity. High dose dexamethasone is excessively toxic in older adults and should be avoided. The roles for high-dose therapy with autologous stem cell transplant or intermediate-dose melphalan with autologous stem cell transplant in older adults with MM in the era of modern therapy remain to be defined. In summary, there are a number of new therapeutic options for older adults with MM, allowing an individualized treatment strategy based on the patient's comorbidities and goals of care.
- Published
- 2012
35. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
- Author
-
Pamela S, Becker, Hagop M, Kantarjian, Frederick R, Appelbaum, Stephen H, Petersdorf, Barry, Storer, Sherry, Pierce, Jianqin, Shan, Paul C, Hendrie, John M, Pagel, Andrei R, Shustov, Derek L, Stirewalt, Stephan, Faderl, Elizabeth, Harrington, and Elihu H, Estey
- Subjects
Adult ,Male ,Risk ,Salvage Therapy ,Maximum Tolerated Dose ,Remission Induction ,Cytarabine ,Kaplan-Meier Estimate ,Middle Aged ,Infections ,Article ,Leukemia, Myeloid, Acute ,Young Adult ,Recurrence ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,Humans ,Female ,Chemical and Drug Induced Liver Injury ,Aged ,Proportional Hazards Models - Abstract
This phase I/II study was conducted to determine the maximum tolerated dose, toxicity, and efficacy of clofarabine in combination with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming (GCLAC), in the treatment of patients with relapsed or refractory acute myeloid leukaemia (AML). Dose escalation of clofarabine occurred without dose-limiting toxicity, so most patients were treated at the maximum dose, 25 mg/m(2) per day with cytarabine 2 g/m(2) per day, each for 5 d, and G-CSF 5 μg/kg, beginning the day before chemotherapy and continuing daily until neutrophil recovery. The complete remission (CR) rate among the 46 evaluable patients was 46% (95% confidence interval [CI] 31-61%) and the CR + CR but with a platelet count100 × 10(9)/l rate was 61% (95% CI 45-75%). Multivariate analysis showed that responses to GCLAC were independent of age, cytogenetic risk category, and number of prior salvage regimens. GCLAC is highly active in relapsed and refractory AML and warrants prospective comparison to other regimens, as well as study in untreated patients.
- Published
- 2011
36. A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation
- Author
-
Alexander Fefer, Ted Gooley, Stephen H. Petersdorf, Edus H. Warren, Frederick R. Appelbaum, Yoshihiro Inamoto, Brenda M. Sandmaier, Jean E. Sanders, Paul J. Martin, Mary E.D. Flowers, and Rainer Storb
- Subjects
medicine.medical_specialty ,Maximum Tolerated Dose ,medicine.medical_treatment ,Salvage therapy ,Graft vs Host Disease ,Antineoplastic Agents ,Hematopoietic stem cell transplantation ,Gastroenterology ,Donor lymphocyte infusion ,Article ,Internal medicine ,Medicine ,Humans ,Transplantation, Homologous ,Recurrent malignancy ,Salvage Therapy ,Acute leukemia ,Chemotherapy ,Transplantation ,Hematopoietic cell transplantation ,Leukemia ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,medicine.disease ,Surgery ,Treatment ,Regimen ,Lymphocyte Transfusion ,Acute Disease ,Interleukin-2 ,business - Abstract
The efficacy of donor lymphocyte infusion (DLI) for treatment of relapsed acute leukemia after allogeneic hematopoietic cell transplantation is limited. We hypothesized that interleukin-2 (IL-2) combined with DLI after chemotherapy might augment graft-versus-leukemia effects. To identify a safe and effective IL-2 regimen, a phase I/II study of DLI plus IL-2 therapy was performed for such patients. After chemotherapy, 17 patients received DLI (1 × 10(8) CD3/kg for patients with related donors, and 0.1 × 10(8) CD3/kg for those with unrelated donors) and an escalating dose of induction IL-2 (1.0, 2.0, or 3.0 × 10(6) IU/m(2)/day representing levels I [n = 7], Ia [n = 9], and II [n = 1]) for 5 days followed by maintenance (1.0 × 10(6) IU/m(2)/day) for 10 days as a continuous intravenous infusion. Unacceptable IL-2-related toxicities developed in 1 patient at level I, 2 at level Ia, and 1 at level II. Grades III-IV acute graft-versus-host disease (aGVHD) developed in 5 patients, and extensive chronic GVHD (cGVHD) developed in 8. Eight patients had a complete remission after chemotherapy prior to DLI, and 2 additional patients had a complete remission after DLI plus IL-2 therapy. In conclusion, the maximal tolerated induction dose of IL-2 combined with DLI appears to be 1.0 × 10(6) IU/m(2)/day. IL-2 administration after DLI might increase the incidence of cGVHD.
- Published
- 2011
37. Efficacy and Safety of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R) in Patients with Relapsed/Refractory Lymphoma: A Prospective Multi-center Phase II Study of by the Puget Sound Oncology Consortium (PSOC)
- Author
-
Oliver W. Press, Julie C. Smith, Stephen H. Petersdorf, George F. Gjerset, Mitchell Garrison, Jasmine T. Daniels, John M. Pagel, Anne E. Murphy, Ajay K. Gopal, Matthew Lonergan, Ted Gooley, and Andrei R. Shustov
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lymphoma ,Phases of clinical research ,Salvage therapy ,Gastroenterology ,Deoxycytidine ,Article ,Dexamethasone ,Carboplatin ,chemistry.chemical_compound ,Antibodies, Monoclonal, Murine-Derived ,Young Adult ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Prospective Studies ,Survival rate ,Aged ,Salvage Therapy ,Peripheral Blood Stem Cell Transplantation ,business.industry ,Remission Induction ,Antibodies, Monoclonal ,Hematology ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Gemcitabine ,Hematopoietic Stem Cell Mobilization ,Surgery ,Survival Rate ,Regimen ,Treatment Outcome ,Oncology ,chemistry ,Drug Resistance, Neoplasm ,Rituximab ,Female ,Neoplasm Recurrence, Local ,business ,Febrile neutropenia ,medicine.drug - Abstract
We conducted a multi-center phase II trial of gemcitabine (G), carboplatin (C), dexamethasone (D), and rituximab (R) in order to examine its safety and efficacy as an outpatient salvage regimen for lymphoma. Fifty-one patients received 2-4 21-day cycles of G (1000 mg/m(2), days 1 and 8), C (AUC = 5, day 1), D (40 mg, daily days 1-4), and R (375 mg/m(2), day 8 for CD20-positive disease) and were evaluable for response. Characteristics included: median age 58 years (19-79 years), stage III/IV 88%, elevated LDH 33%, median prior therapies 2, prior stem cell transplant 12%, chemoresistant 62%, median prior remission duration 2.5 months. The overall and complete response rates were 67% (95% confidence interval [CI] 54-80%) and 31% (95% CI 19-44%), respectively, with activity seen in a broad variety of histologies. Responses occurred in 16 of 17 (94%, 95% CI 83-100%) transplant-eligible patients and 15 of 28 (54%, 95% CI 34-71%) with chemoresistant disease. The median CD34 yield in patients attempting peripheral blood stem cell (PBSC) collection following this regimen was 10.9 x 10(6) CD34+ cells/kg (range 5.0-24.1 x 10(6)). Hematologic toxicity was common, but febrile neutropenia (2.5%) and grade 4 non-hematologic adverse events (n = 2) were rare, with no treatment-related deaths. GCD(R) is a safe and effective outpatient regimen for relapsed lymphoma, and successfully mobilizes PBSCs.
- Published
- 2010
38. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience
- Author
-
Oliver W. Press, Tracee L. Metcalfe, Stephen H. Petersdorf, Ted Gooley, David G. Maloney, William I. Bensinger, Ajay K. Gopal, John M. Pagel, and Leona Holmberg
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Transplantation Conditioning ,medicine.medical_treatment ,Salvage therapy ,Hematopoietic stem cell transplantation ,Transplantation, Autologous ,Article ,Autologous stem-cell transplantation ,Nodular sclerosis ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Refractory Hodgkin Lymphoma ,Humans ,Progression-free survival ,Survival rate ,Neoplasm Staging ,Salvage Therapy ,business.industry ,Hematopoietic Stem Cell Transplantation ,Total body irradiation ,Middle Aged ,medicine.disease ,Hodgkin Disease ,Surgery ,Survival Rate ,Treatment Outcome ,Drug Resistance, Neoplasm ,Female ,business - Abstract
BACKGROUND. High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), but this therapy is commonly denied to patients with resistant disease. We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients. METHODS. Sixty-four chemoresistant HL patients underwent HDT followed by ASCT at our center. Baseline characteristics included median age = 35 years (range, 14-59 years), stage III/IV = 49 (77%), nodular sclerosis histology = 51 (80%), and prior radiation = 32 (50%). Twenty-six patients (41%) received total body irradiation (TBI)-based regimens, and 38 (59%) underwent non-TBI conditioning. RESULTS. The estimated 5-year overall survival (OS) and progression-free survival (PFS) were 31% and 17%, respectively (median follow-up = 4.2 years). Multivariate analysis only identified year of transplant as independently associated with improved OS (P = .008) and PFS (P = .04), with patients receiving transplants in later years having better outcome. The probabilities of 3-year PFS for patients receiving transplants during 1986 to 1989, 1990 to July 1993, August 1993 to 1999, and 2000 to 2005 were 9%, 21%, 33%, and 31%, respectively. CONCLUSIONS. These data suggest that HDT and ASCT may result in prolonged remissions and survival for a subset of chemoresistant HL patients, with improved outcomes in patients receiving transplants more recently. Cancer 2008. © 2008 American Cancer Society.
- Published
- 2008
39. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438)
- Author
-
John A. Thompson, Stephen J. Forman, Oliver W. Press, Alexander Fefer, Joseph M. Unger, Michael LeBlanc, Patrick J. Stiff, Auayporn Nademanee, Stephen H. Petersdorf, and Richard I. Fisher
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Randomization ,Cyclophosphamide ,Clinical Trials and Observations ,Immunology ,Antineoplastic Agents ,Biochemistry ,Transplantation, Autologous ,Disease-Free Survival ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,law ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Etoposide ,Peripheral Blood Stem Cell Transplantation ,business.industry ,Lymphoma, Non-Hodgkin ,Hazard ratio ,Neoplasms, Second Primary ,Cell Biology ,Hematology ,Total body irradiation ,Middle Aged ,Combined Modality Therapy ,Nitrogen mustard ,Transplantation ,Treatment Outcome ,chemistry ,Interleukin-2 ,Female ,business ,Whole-Body Irradiation ,medicine.drug - Abstract
To determine the effect of posttransplantation immunotherapy with IL-2 on the progression-free survival (PFS) and overall survival (OS) of patients with non-Hodgkin lymphoma (NHL) after autologous stem-cell transplantation (PBSCT), patients with previously treated NHL were treated with cyclophosphamide, etoposide, total body irradiation (TBI), and PBSCT. Twenty-eight to 80 days after PBSCT, patients were randomized to IL-2 versus observation. Three hundred seventy-six eligible patients were registered (with 4-year PFS of 34% and 4-year OS of 52%), and 194 eligible patients were randomized to continuous infusion intravenous IL-2 (9 million units/m2/day for 4 days followed 5 days later by 1.6 million units/m2/day for 10 days) versus observation. In randomized patients, there was no significant difference in PFS (hazard ratio of IL-2 to observation = 0.90; P =.56) or in OS (hazard ratio of IL-2 to observation = 0.88; P =.55). There were no deaths related to IL-2 treatment. Grade 4 IL-2–related toxicities (n = 14) were reversible. These results confirm earlier SWOG findings that cyclophosphamide, etoposide, TBI, and PBSCT can be administered to patients with relapsed/refractory NHL with encouraging PFS and OS. Posttransplantation IL-2 given at this dose and schedule of administration had no significant effect on PFS or OS. This study is registered at www.clinicaltrials.gov as NCT00002649.
- Published
- 2008
40. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
- Author
-
E. Frank, Paul Kirschmeier, Jeffrey H. Lipton, Josy Reiffers, Stephen G. O'Brien, Johan Lanng Nielsen, Alan F. List, Giovanni Martinelli, Eric J. Feldman, François Guilhot, Yali Zhu, Stephen H. Petersdorf, Tessa L. Holyoake, Gail J. Roboz, Paul Statkevich, S. Loechner, A R Turner, Philippe Colombat, Jorge E. Cortes, Daniel J. DeAngelo, Bengt Simonsson, Juliet N. Barker, Frédéric Maloisel, Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O'Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, Martinelli G, Nielsen JL, Petersdorf S, Guilhot F, Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S, and List A.
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Maximum Tolerated Dose ,Gastrointestinal Diseases ,Pyridines ,Nausea ,medicine.medical_treatment ,MYELODISPLASTIC SYNDROME ,Chronic myelomonocytic leukemia ,Anorexia ,Gastroenterology ,chemistry.chemical_compound ,Piperidines ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Farnesyltranstransferase ,Humans ,Lonafarnib ,Enzyme Inhibitors ,Aged ,Aged, 80 and over ,Chemotherapy ,Hematology ,business.industry ,Remission Induction ,Farnesyltransferase inhibitor ,CHRONIC MYELOMONOCYTIC LEUKEMIA ,Leukemia, Myelomonocytic, Chronic ,LONAFARNIB ,Middle Aged ,medicine.disease ,Leukemia ,Treatment Outcome ,Oncology ,chemistry ,Myelodysplastic Syndromes ,Immunology ,Drug Monitoring ,medicine.symptom ,business - Abstract
Udgivelsesdato: 2008-Sep Lonafarnib is an orally bio-available farnesyltransferase inhibitor that prevents farnesylation of specific target proteins including Ras. In a multicenter study, 67 patients with advanced myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) were treated with a continuous oral dose of 200-300 mg of lonafarnib and were evaluated for hematologic, pathologic and pharmacodynamic response. The median age of patients was 70 years (range 44-86). There were 32 patients with MDS (RAEB-20 and RAEB-t-12) and 35 with CMML. Overall 16 (24%) of the patients responded with two patients achieving a complete remission and one a partial response. Responses were seen in 6/32 and 10/35 patients with MDS and CMML, respectively. Of the 19 patients who were platelet transfusion-dependent prior to treatment, 5 (26%) became transfusion-free for a median duration of 185 days. A decrease in the farnesylation of the HDJ-2 protein measured in patient-derived cells was observed in the majority of patients during treatment with lonafarnib, but no clear correlation between changes in farnesylation and clinical effect could be made. Gastrointestinal toxicity was significant with 19% of patients discontinuing therapy due to diarrhea, nausea and/or anorexia. Lonafarnib has demonstrable activity in patients with advanced MDS and CMML.
- Published
- 2008
41. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma
- Author
-
Leona Holmberg, William I. Bensinger, Rosalyn N. Pham, Oliver W. Press, Ted Gooley, Harvey A. Greisman, Stephen H. Petersdorf, John M. Pagel, Ajay K. Gopal, Grant E. Keeney, and David G. Maloney
- Subjects
Adult ,Male ,endocrine system ,medicine.medical_specialty ,Pathology ,Transplantation Conditioning ,Follicular lymphoma ,Antineoplastic Agents ,Kaplan-Meier Estimate ,Transplantation, Autologous ,Cohort Studies ,Autologous stem-cell transplantation ,hemic and lymphatic diseases ,Histologic grade ,Internal medicine ,medicine ,Humans ,Lymphoma, Follicular ,Aged ,Retrospective Studies ,Transplantation ,Hematology ,Dose-Response Relationship, Drug ,business.industry ,Hematopoietic Stem Cell Transplantation ,Cancer ,Middle Aged ,medicine.disease ,Prognosis ,Combined Modality Therapy ,High dose therapy ,Disease Progression ,Histopathology ,Female ,Radiotherapy, Adjuvant ,Stem cell ,business - Abstract
The impact of the follicular lymphoma (FL) histologic grade on outcomes after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) is unknown. We evaluated 219 consecutive patients with grades 1-3 FL who underwent HDT and ASCT at our center. Overall survival (OS), progression-free survival (PFS), relapse and non-relapse mortality (NRM) was estimated for each grade after controlling for other predictive factors. The number of patients with grades 1, 2 and 3 FL was 106 (48%), 75 (34%) and 38 (17%), respectively. Five-year outcome estimates for the entire cohort included 60% OS, 39% PFS and 46% relapse (median follow-up=7.8 years). PFS and relapse were nearly identical among patients with grade 3 FL versus grades 1-2 FL after adjusting for other contributing factors (hazard ratio (HR)=0.90, P=0.68; HR=1.07, P=0.80, respectively). The hazard for mortality (HR=0.70, P=0.23) and NRM (HR=0.33, P=0.07) was non-significantly lower among patients with grade 3 FL compared to patients with grades 1-2 disease. Factors associated with inferior PFS included elevated lactate dehydrogenase (HR=1.52, P=0.03), chemoresistance (HR=1.82, P=0.02),or =2 prior therapies (HR=1.8, P=0.03) and prior radiation (HR=1.99, P=0.003). These data suggest that the histologic grade of FL does not impact PFS or relapse following HDT and ASCT.
- Published
- 2007
42. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adultsor = 60 years old with relapsed or refractory B-cell lymphoma
- Author
-
David G. Maloney, Stephen H. Petersdorf, Darrell R. Fisher, Ted Gooley, Frederick R. Appelbaum, Oliver W. Press, John M. Pagel, Janet F. Eary, Joseph G. Rajendran, and Ajay K. Gopal
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Lymphoma, B-Cell ,medicine.medical_treatment ,Antineoplastic Agents ,Hematopoietic stem cell transplantation ,Tositumomab ,Iodine Radioisotopes ,Refractory ,Internal medicine ,Medicine ,Humans ,Anti cd20 ,Aged ,Chi-Square Distribution ,business.industry ,Hematopoietic Stem Cell Transplantation ,Antibodies, Monoclonal ,Radiotherapy Dosage ,Middle Aged ,Radioimmunotherapy ,medicine.disease ,Antigens, CD20 ,Combined Modality Therapy ,Survival Analysis ,Lymphoma ,Radiation therapy ,Treatment Outcome ,Disease Progression ,Female ,Stem cell ,business ,Nuclear medicine ,medicine.drug - Abstract
Purpose The majority of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) are older than 60 years, yet they are often denied potentially curative high-dose therapy and autologous stem-cell transplantations (ASCT) because of the risk of excessive treatment-related morbidity and mortality. Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites while limiting exposure to normal organs and may be particularly suited for older adults requiring high-dose therapy. Patients and Methods Patients older than 60 years with relapsed B-cell NHL (B-NHL) received infusions of tositumomab anti-CD20 antibody labeled with 185 to 370 Mbq (5 to 10 mCi) [131I]-tracer for dosimetry purposes followed 10 days later by individualized therapeutic infusions of [131I]tositumomab (median, 19.4 Gbq [525 mCi]; range, 12.1 to 42.7 Gbq [328 to 1,154 mCi]) to deliver 25 to 27 Gy to the critical normal organ receiving the highest radiation dose. ASCT was performed approximately 2 weeks after therapy. Results Twenty-four patients with a median age of 64 years (range, 60 to 76 years), who had received a median of four prior regimens (range, two to 14 regimens), were treated. Thirteen patients (54%) had chemotherapy-resistant disease. The estimated 3-year overall and progression-free survival rates were 59% and 51%, respectively, with a median follow-up of 2.9 years (range, 1 to 6 years). All patients experienced expected myeloablation with engraftment of platelets (≥ 20 K/μL) and neutrophils (≥ 500/μL), occurring at a median of 9 and 15 days after ASCT, respectively. There were no treatment-related deaths, and only two patients experienced grade 4 nonhematologic toxicity. Conclusion Myeloablative RIT and ASCT is a safe and effective therapeutic option for older adults with relapsed B-NHL.
- Published
- 2007
43. Benchmarks in Clinical Productivity: A National Comprehensive Cancer Network Survey
- Author
-
Robert P. Witherspoon, Andrew Ziskind, Brian McKenna, Jennifer M. Dodson, Stephen H. Petersdorf, Robert L. Wasserman, Jane Weeks, Clara D. Bloomfield, F. Marc Stewart, Barry Storer, Marcy B. Waldinger, Sara Perkel, Frederick R. Appelbaum, and William P. Vaughan
- Subjects
Relative value ,medicine.medical_specialty ,Oncology (nursing) ,business.industry ,Health Policy ,Alternative medicine ,Cancer ,Practice management ,Bioinformatics ,medicine.disease ,Oncology ,Order (exchange) ,Software deployment ,Medicine ,Operations management ,business ,Productivity ,Original Research - Abstract
Purpose Oncologists in academic cancer centers usually generate professional fees that are insufficient to cover salaries and other expenses, despite significant clinical activity; therefore, supplemental funding is frequently required in order to support competitive levels of physician compensation. Relative value units (RVUs) allow comparisons of productivity across institutions and practice locations and provide a reasonable point of reference on which funding decisions can be based. Methods We reviewed the clinical productivity and other characteristics of oncology physicians practicing in 13 major academic cancer institutions with membership or shared membership in the National Comprehensive Cancer Network (NCCN). The objectives of this study were to develop tools that would lead to better-informed decision making regarding practice management and physician deployment in comprehensive cancer centers and to determine benchmarks of productivity using RVUs accrued by physicians at each institution. Three hundred fifty-three individual physician practices across the 13 NCCN institutions in the survey provided data describing adult hematology/medical oncology and bone marrow/stem-cell transplantation programs. Data from the member institutions participating in the survey included all American Medical Association Current Procedural Terminology (CPT®) codes generated (billed) by each physician during each organization's fiscal year 2003 as a measure of actual clinical productivity. Physician characteristic data included specialty, clinical full-time equivalent (CFTE) status, faculty rank, faculty track, number of years of experience, and total salary by funding source. The average adult hematologist/medical oncologist in our sample would produce 3,745 RVUs if he/she worked full-time as a clinician (100% CFTE), compared with 4,506 RVUs for a 100% CFTE transplant oncologist. Results and Conclusion Our results suggest specific clinical productivity targets for academic oncologists and provide a methodology for analyzing potential factors associated with clinical productivity and developing clinical productivity targets specific for physicians with a mix of research, administrative, teaching, and clinical salary support.
- Published
- 2007
44. Age and acute myeloid leukemia
- Author
-
Holly Gundacker, Frederick R. Appelbaum, David R. Head, Marilyn L. Slovak, Cheryl L. Willman, Stephen H. Petersdorf, John E. Godwin, and Jeanne E. Anderson
- Subjects
Adult ,Male ,medicine.medical_specialty ,Myeloid ,Adolescent ,Clinical Trials and Observations ,Immunology ,Biochemistry ,Cytogenetics ,Leukocyte Count ,Internal medicine ,White blood cell ,medicine ,Humans ,Aged ,Retrospective Studies ,Chromosome Aberrations ,Performance status ,business.industry ,Incidence (epidemiology) ,Age Factors ,Myeloid leukemia ,Retrospective cohort study ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Prognosis ,Surgery ,Leukemia ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Female ,business - Abstract
We conducted a retrospective analysis of 968 adults with acute myeloid leukemia (AML) on 5 recent Southwest Oncology Group trials to understand how the nature of AML changes with age. Older study patients with AML presented with poorer performance status, lower white blood cell counts, and a lower percentage of marrow blasts. Multidrug resistance was found in 33% of AMLs in patients younger than age 56 compared with 57% in patients older than 75. The percentage of patients with favorable cytogenetics dropped from 17% in those younger than age 56 to 4% in those older than 75. In contrast, the proportion of patients with unfavorable cytogenetics increased from 35% in those younger than age 56 to 51% in patients older than 75. Particularly striking were the increases in abnormalities of chromosomes 5, 7, and 17 among the elderly. The increased incidence of unfavorable cytogenetics contributed to their poorer outcome, and, within each cytogenetic risk group, treatment outcome deteriorated markedly with age. Finally, the combination of a poor performance status and advanced age identified a group of patients with a very high likelihood of dying within 30 days of initiating induction therapy. The distinct biology and clinical responses seen argue for age-specific assessments when evaluating therapies for AML.
- Published
- 2006
45. Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG
- Author
-
Marie-Christianne Vekemans, Harry P. Erba, Thomas Pabst, Roland B. Walter, Frederick R. Appelbaum, Megan Othus, Stephen H. Petersdorf, Elihu H. Estey, Bob Löwenberg, and Gert J. Ossenkoppele
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Proportional hazards model ,medicine.medical_treatment ,Immunology ,Population ,Hazard ratio ,Induction chemotherapy ,Salvage therapy ,Cell Biology ,Hematology ,Biochemistry ,Surgery ,Clinical trial ,Internal medicine ,Cohort ,medicine ,business ,education ,Neoadjuvant therapy - Abstract
Background: Therapeutic resistance, i.e. the failure to achieve complete remission (CR) or relapse from CR, is common in adult acute myeloid leukemia (AML). It is well recognized that the likelihood of complete remission (CR) and survival after receipt of therapy for relapsed/refractory AML (Òsalvage therapyÓ) varies widely with prior response duration being the primary predictor of both outcomes. One approach to salvage therapy trials would permit inclusion regardless of prior CR duration (CRD) given the possibility that a new drug might only be effective with longer CRD and that even with longer CRD standard therapies are hardly satisfactory. A second, more common approach relies on CRD to create a ÒhomogenousÓ population to facilitate data interpretation; yet, various arbitrary CRD cut-points have been used. This work examines whether a particular CRD might be used based on the relation between CRD and subsequent survival. Methods: We used information on patients with newly diagnosed AML other than acute promyelocytic leukemia receiving curative-intent treatment on 5 trials conducted by the Dutch-Belgian Cooperative Trial Group for Hematology/Oncology and the Swiss Group for Clinical Cancer Research (HOVON/SAKK; n=1,306) or on the SWOG S0106 trial (n=586). Failure was considered as completion of induction therapy without CR (CRD=0) or as relapse from CR. Survival after failure (SAF) was measured from the date of completing protocol induction therapy without report of CR or from the date of relapse, with SAF measured until the date of death from any cause with patients last known to be alive censored at the date of last contact. SAF was estimated using the Kaplan-Meier method. Cox regression was used to analyze the association between SAF and CR duration; the latter was modeled both quantitatively and categorically. Regression analyses with all three cohorts were stratified by cohort. Results: Among the 1,892 patients, 1,026 (54%) patients (median age: 48 years [range: 15-77 years]) failed induction therapy (n=430) or had a first CR duration of 2 years or less (n=596) and were included in our analyses. In the total patient cohort as well as in both treatment sites, longer CR duration was associated with longer SAF. In the total patient cohort, there was no evidence that the SAF for patients with first CR duration of 6 months or less was different or better than the SAF for patients who were primary refractory to induction therapy (see table). The same conclusion could be drawn when analyzing patients treated on HOVON/SAKK trials as separate cohort. In the SWOG cohort, there was no evidence that SAF with patients with first CR duration of 9 months or less was different or better than SAF of patients who were refractory to induction therapy. Conclusions: Limitations of this work include incomplete information about whether primary induction failures received 1 or 2 induction courses before failure was declared and about the therapy received after failure, as well as the presence of inter-cohort heterogeneity. Nonetheless, assuming SAF is a crucial endpoint and using data to establish its relation with CRD, our study indicates that patients who are primary refractory to 1-2 courses of intensive induction chemotherapy or who relapse within 6 months have distinctly different SAF than patients who relapse after a CR duration of more than 6 months. Regardless of whether these 2 subsets are deemed equally eligible for trials, our data could form the basis for rational stratification of patients enrolled on a trial for relapsed/refractory AML. Table 1: Hazard ratio (95% confidence interval) for Cox regression models for survival after failure (SAF). HOVON/SAKK(n=685) SWOG(n=341) All Patients(n=1,026) Failed Induction (Reference) (Reference) (Reference) CR 0-3 months 0.92 (0.69-1.23) 1.70 (0.96-3.02) 1.08 (0.83-1.40) CR 3-6 months 1.05 (0.83-1.32) 1.67 (1.07-2.62) 1.20 (0.98-1.47) CR 6-9 months 0.64 (0.51-0.81) 1.25 (0.84-1.87) 0.77 (0.63-0.94) CR 9-12 months 0.43 (0.31-0.59) 0.88 (0.59-1.30) 0.56 (0.43-0.72) CR 1-2 years 0.39 (0.30-0.52) 0.55 (0.36-0.83) 0.45 (0.35-0.56) Disclosures Petersdorf: Author deceased: Author recently deceased Other.
- Published
- 2014
46. Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML
- Author
-
John Slattery, Bart L. Scott, Frederick R. Appelbaum, Barry Storer, H. Joachim Deeg, Stephen H. Petersdorf, and Thomas R. Chauncey
- Subjects
Oncology ,Adult ,Graft Rejection ,Male ,Cancer Research ,medicine.medical_specialty ,Transplantation Conditioning ,Cyclophosphamide ,Adolescent ,Graft vs Host Disease ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,In patient ,Child ,Busulfan ,Aged ,Hematopoietic cell ,business.industry ,Hematopoietic Stem Cell Transplantation ,Infant ,Hematology ,Donor status ,Total body irradiation ,Middle Aged ,Surgery ,Transplantation ,Survival Rate ,Leukemia, Myeloid, Acute ,Child, Preschool ,Myelodysplastic Syndromes ,Toxicity ,Female ,business ,medicine.drug - Abstract
Hematopoietic cell transplantation is the only curative therapy for patients with myelodysplasia (MDS). However, treatment-related toxicity and, in patients with advanced MDS (RAEB, RAEB-T) and those who have transformed to AML (tAML), post-transplant relapse continues to be problematic. We reviewed results in 128 patients with advanced MDS and tAML transplanted from HLA-identical related or unrelated donors after preparation with myeloablative conditioning regimens. Seventy-eight patients were conditioned with busulfan (Bu), prescribed dose 16 mg/kg, adjusted to achieve plasma concentrations of 800-900 ng/ml, plus cyclophosphamide (Cy), 2 x 60 mg/kg [tBuCy], and 50 patients were conditioned with Bu 7 mg/kg (without dose adjustment) and total body irradiation (TBI) 6 x 200 cGy given over 3 days [BuTBI]. There was no statistically significant difference in regards to overall survival, relapse-free survival (RFS), or non-relapse mortality (NRM) between the 2 regimens regardless of donor status. However, there was a trend towards higher rates of relapse (HR 1.33, P=0.38) and lower rates of NRM (HR 0.61, P=0.09) in patients conditioned with tBuCy. The increased rate of relapse seen with tBuCy was significant when restricted to only those patients with a diagnosis of RAEB (HR 4.50, P=0.02). Patients given BuTBI had a higher incidence of GvHD; however, the incidence of GvHD regardless of grade did not differ significantly between patients who relapsed and those who did not. Thus, in patients with advanced MDS/tAML, the use of a less toxic conditioning regimen resulted in a non-significant overall gain in RFS largely due to lower rates of NRM. New concepts of conditioning regimens are needed which reduce toxicity without increasing the risk of relapse.
- Published
- 2004
47. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy
- Author
-
Thomas R. Fritsche, Lloyd Mancl, Joel B. Epstein, Oliver W. Press, Stephen H. Petersdorf, Kimberly Hanson-Huggins, Joshua D. Epstein, Alice Chen, and Edmond L. Truelove
- Subjects
Adult ,Male ,Nystatin ,medicine.medical_specialty ,Antifungal Agents ,Time Factors ,Adolescent ,Mouthwashes ,Administration, Oral ,Polyenes ,Severity of Illness Index ,Gastroenterology ,Gingivitis ,Candidiasis, Oral ,Amphotericin B ,Internal medicine ,medicine ,Mucositis ,Humans ,Antibiotic prophylaxis ,Adverse effect ,Fluconazole ,Aged ,Mouth ,business.industry ,Hematopoietic Stem Cell Transplantation ,Antibiotic Prophylaxis ,Middle Aged ,medicine.disease ,Gingivitis, Necrotizing Ulcerative ,Treatment Outcome ,Oncology ,Tolerability ,Immunology ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
The effectiveness of amphotericin B oral suspension versus nystatin oral suspension for the prevention of oral colonization by Candida in hematopoietic cell transplant (HCT) patients was examined.Prior to hematopoietic cell infusion, 40 patients receiving systemic fluconazole for prophylaxis were randomized to receive either amphotericin B oral suspension or nystatin oral suspension, q.i.d. The study continued to day 21 or until the patient was discharge from the hospital or withdrawn from the study. Oral examinations were conducted twice weekly, and adverse events and compliance were recorded. Cultures were taken for quantitative counts and species identification. Candida isolates were assessed for resistance to the oral antifungal agents. Blood was collected for assessment of amphotericin B levels.Ulcerative mucositis occurred in 84.6% of patients undergoing HCT, and no correlation was observed between the severity of mucositis and the presence of oral Candida and the severity of mucositis. Systemic and topical antifungal treatment resulted in a decrease in the number of colonized patients (54.8% before treatment; 23.1% during treatment); however, oral colonization was not eliminated. Tolerability of the oral rinse products was limited, with greater noncompliance in the amphotericin B than the nystatin group. Reports of altered taste appeared to be greater in the amphotericin B group. Minimal absorption of amphotericin B was seen following oral rinsing (serum levels 0.12-0.50 microg/ml), and no consistent changes in organism susceptibility to polyenes were seen. The results suggest that topical antifungal rinses may further control oropharyngeal colonization by Candida in patients on systemic antifungals receiving HCT, but the effect is limited by tolerability and reformulation and should be considered in order to increase compliance.
- Published
- 2004
48. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
- Author
-
Ted Gooley, Lawrence D. Durack, Joseph Rajendran, Dana C. Matthews, Frederick R. Appelbaum, Oliver W. Press, Ajay K. Gopal, Janet F. Eary, Brent L. Wood, Stephen H. Petersdorf, David G. Maloney, Sharon A. Bush, Irwin D. Bernstein, and Paul J. Martin
- Subjects
Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Lymphoma, Mantle-Cell ,Biochemistry ,Gastroenterology ,Transplantation, Autologous ,Tositumomab ,Disease-Free Survival ,Iodine Radioisotopes ,Autologous stem-cell transplantation ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Survival rate ,Etoposide ,Salvage Therapy ,business.industry ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Antibodies, Monoclonal ,Cell Biology ,Hematology ,Middle Aged ,Radioimmunotherapy ,medicine.disease ,Combined Modality Therapy ,Surgery ,Transplantation ,Survival Rate ,Refractory Mantle Cell Lymphoma ,Mantle cell lymphoma ,business ,medicine.drug - Abstract
Relapsed mantle cell lymphoma is a radiation-sensitive malignancy that is unlikely to be cured by treatment with conventional high-dose therapy and autologous stem cell transplantation. We tested the safety and efficacy of using a CD20-specific monoclonal antibody conjugated with 131I to deliver high-dose radiation selectively to all lymphoma sites. Patients with relapsed or refractory mantle cell lymphoma received infusions of 131I-labeled CD20-specific monoclonal antibody (Tositumomab). The antibody dose was 1.7 mg/kg body weight, and the amount of 131I was calibrated to deliver 20 to 25 Gy to vital normal organs. This treatment was followed 10 days later by administration of high-dose etoposide (30-60 mg/kg), cyclophosphamide (60-100 mg/kg), and infusion of cryopreserved autologous stem cells. The 16 patients in this study had received a median of 3 prior treatments, and 7 had chemotherapy-resistant disease. The median dose of 131I was 510 mCi (18.87 GBq). There were no therapy-related deaths. Among the 11 patients with conventionally measurable disease at the time of treatment, the respective complete and overall response rates were 91% and 100%. Fifteen patients remain alive, and 12 have had no progression of lymphoma at 6 to 57 months from transplantation and 16 to 97 months from diagnosis. Overall survival at 3 years from transplantation is estimated at 93%, and progression-free survival is estimated at 61%. High-dose treatment with 131I-Tositumomab, etoposide, and cyclophosphamide results in a high remission rate and may provide long-term disease-free survival for patients with relapsed or refractory mantle cell lymphoma.
- Published
- 2002
49. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study
- Author
-
Frederick R. Appelbaum, Vivek Roy, Kenneth J. Kopecky, Stanley P. Balcerzak, David H. Boldt, Theodore Wun, Stephen H. Petersdorf, R. W. Veith, and David R. Head
- Subjects
Adult ,Cancer Research ,Vincristine ,medicine.medical_specialty ,Cyclophosphamide ,medicine.medical_treatment ,Gastroenterology ,Disease-Free Survival ,Tioguanine ,Maintenance therapy ,Acute lymphocytic leukemia ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Asparaginase ,Humans ,Chemotherapy ,Dose-Response Relationship, Drug ,business.industry ,Remission Induction ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Survival Analysis ,Surgery ,Regimen ,Methotrexate ,Oncology ,Cytarabine ,business ,medicine.drug - Abstract
The effectiveness of intensive post-remission chemotherapy regimens for adult patients with acute lymphoblastic leukemia (ALL) is limited by both a high rate of disease recurrence and a substantial incidence of treatment toxicity. To evaluate a potentially more effective and less toxic approach, we conducted a multicenter phase III trial of consolidation therapies comparing the standard L10M regimen with one combining the brief, intensive L17M regimen and escalating methotrexate (MTX) and L-asparaginase (L-asp). Patients over age 15 with previously untreated ALL were eligible. Induction therapy included vincristine, prednisone, doxorubicin, cyclophosphamide and intrathecal methotrexate administered over 36 days. Patients who achieved complete remission (CR) were randomized to receive consolidation with either the L10M regimen or with DAT (daunomycin, cytosine arabinoside, 6-thioguanine) and escalating MTX and L-asp. The randomization was stratified by age, WBC and Ph chromosome status. Maintenance therapy was the same in both arms. Of 353 eligible patients, 218 (62%) achieved CR and 195 were randomized. The treatment arms did not differ significantly with respect to disease-free survival (DFS; P= 0.46) or overall survival (P= 0.39). Estimated DFS at 5 years was 32% (95% confidence interval (CI) 23-42%) in the L10M arm and 25% (95% CI 16-33%) in the DAT/MTX/L-asp arm. In each arm, 4% of patients died of toxicities (infection in all but one case). Infections and nausea/vomiting were somewhat more common in the L10M arm (occurring in 68% and 53% of patients respectively) than the DAT/MTX/L-asp arm (56% and 33%). The DAT/MTX/L-asp consolidation regimen was associated with some reduction in nonfatal toxicities, but no significant improvement in DFS, overall survival or non-relapse mortality when compared to the standard L10M regimen.
- Published
- 2001
50. A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL)
- Author
-
David G. Maloney, Kelly M. Smith, Britt E Kammerer, Troy Wadsworth, Oliver W. Press, Yoshio Inoue, Ajay K. Gopal, Stephen H. Petersdorf, Karl J. Schultheiss, John M. Pagel, Kiarash Kojouri, Trevor W. Dennie, and Raya Mawad
- Subjects
CD20 ,medicine.medical_specialty ,Cyclophosphamide ,biology ,medicine.drug_class ,business.industry ,Immunology ,Histone deacetylase inhibitor ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Surgery ,Fludarabine ,Leukemia ,Maintenance therapy ,Internal medicine ,medicine ,biology.protein ,Rituximab ,business ,Vorinostat ,medicine.drug - Abstract
Background The limitations of current CLL/SLL treatments include suboptimal response rates, variable remission durations, toxicities, and few cures. Vorinostat is a histone deacetylase inhibitor that regulates gene transcription and possibly CD20 expression, leading to its investigative use in the treatment of B-cell malignancies. For this reason, we studied the addition of vorinostat to fludarabine, cyclophosphamide and rituximab (FCR+V) followed by maintenance therapy with rituximab and vorinostat. Methods Patients over age 18 with previously untreated Rai stage I-IV CLL or SLL and ECOG 0-2 were eligible. They received 4-6 cycles of FCR+V followed by up to eight cycles of maintenance with rituximab and vorinostat. Each cycle of FCR used cyclophosphamide 250 mg/m2 IV on days 1-3 and fludarabine 25 mg/m2 IV days 1-3 of each cycle given every 28 days; with rituximab 375 mg/m2 IV once with cycle 1 followed by 500 mg/m2IV once per cycle for cycles 2-6. Rituximab 500 mg/m2 IV was given day 1 of each 3 month cycle of maintenance for up to 8 cycles. Vorinostat was given on days 1-5 and 8-12 of each treatment cycle and days 1-14 of each 3-month maintenance cycle. The Phase I vorinostat starting dose was 200 mg/day and escalated by 100 mg/day to a maximum pre-determined dose of 400 mg/day in a 3 x 3 design. Since no dose limiting toxicity was seen during Phase I, the previously designated maximum dose of 400 mg/day vorinostat was chosen for the Phase II portion of the trial. Results Ten patients were treated on the Phase I portion of the study, and 26 patients have been enrolled in the Phase II portion at the maximum vorinostat dose of 400 mg/day combined with FCR and rituximab maintenance. The median age of patients on study was 58 (range, 36-72); with 6 patients enrolled with Stage I, 15 with Stage II, 5 with Stage III and 10 with Stage IV disease. Nine patients (25%) had >30% CD38 expression, 13 patients (36%) had >20% ZAP70 expression, and 4 patients (11%) had 17p deletions detected by FISH of marrow samples. Median follow-up on study is 15 months (range, 0.9-38.6). Of the 36 patients enrolled, 22 patients are evaluable after completing 4-6 cycles of FCR+V, 1 patient progressed after cycle 2 (del17p), 9 patients are currently receiving FCR+V and 4 patients are unevaluable. Of these 4 patients, one withdrew voluntarily, one was taken off study due to non-compliance, one went off study after cycle 3 due to cytopenias, and one patient with multiple co-morbidities died of sepsis after cycle 5. Of the 22 patients who have completed 4-6 cycles of FCR+V, 16 (73%) obtained a complete response (CR), 5 (22.5%) obtained a partial response (PR), and 1 (4.5%) has stable disease. Of these 22 patients, 4 (18%) have completed 8 cycles of maintenance with rituximab and vorinostat, 5 (23%) were taken off study due to cytopenias, 1 (4.5%) went off study due to insurance issues, 1 (4.5%) went off study due to recurrent infections, 2 (9%) voluntarily withdrew from study, and 9 (41%) are still receiving maintenance therapy. The most common grade 3-4 non-hematologic toxicities during FCR+V were gastrointestinal symptoms in 10 patients and fatigue in 3 patients. However, there were no grade 3-4 non-hematologic toxicities that resulted in patient withdrawal from study during treatment with FCR+V. No grade 3-4 non-hematologic toxicities have been observed in patients who have completed or are undergoing maintenance with rituximab and vorinostat. Conclusion Treatment of CLL/SLL with fludarabine, cyclophosphamide, rituximab and 400mg/day vorinostat (FCR +V) followed by maintenance with rituximab and vorinostat appears feasible and tolerable, and may warrant further study. Disclosures: Gopal: Merck: Research Funding. Press:Roche/Genentech: Consultancy.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.